U.S. patent application number 10/096360 was filed with the patent office on 2003-05-01 for taxoids, their preparation and pharmaceutical compositions containing them.
This patent application is currently assigned to Aventis Pharma, S.A.. Invention is credited to Bouchard, Herve, Bourzat, Jean-Dominique, Commercon, Alain.
Application Number | 20030083497 10/096360 |
Document ID | / |
Family ID | 26229935 |
Filed Date | 2003-05-01 |
United States Patent
Application |
20030083497 |
Kind Code |
A1 |
Bouchard, Herve ; et
al. |
May 1, 2003 |
Taxoids, their preparation and pharmaceutical compositions
containing them
Abstract
New taxoids of general formula (I), their preparation, and
pharmaceutical compounds containing them. 1 In general formula (I),
for example, Ar represents an aryl radical, R represents an
alkoxyacetyl radical, R.sub.1 represents a benzoyl radical or a
radical of formula R.sub.2--O--CO-- in which R.sub.2 represents an
optionally substituted alkyl radical, an alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl
radical. The new products of general formula (I) have a remarkable
antitumor activity.
Inventors: |
Bouchard, Herve; (Ivry Sur
Seine, FR) ; Bourzat, Jean-Dominique; (Vincennes,
FR) ; Commercon, Alain; (Vitry-Sur-Seine,
FR) |
Correspondence
Address: |
FINNEGAN, HENDERSON, FARABOW, GARRETT &
DUNNER LLP
1300 I STREET, NW
WASHINGTON
DC
20006
US
|
Assignee: |
Aventis Pharma, S.A.
|
Family ID: |
26229935 |
Appl. No.: |
10/096360 |
Filed: |
March 13, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10096360 |
Mar 13, 2002 |
|
|
|
09759449 |
Jan 16, 2001 |
|
|
|
6384071 |
|
|
|
|
09759449 |
Jan 16, 2001 |
|
|
|
09126590 |
Jul 31, 1998 |
|
|
|
6194582 |
|
|
|
|
09126590 |
Jul 31, 1998 |
|
|
|
08477518 |
Jun 7, 1995 |
|
|
|
5814658 |
|
|
|
|
08477518 |
Jun 7, 1995 |
|
|
|
08162984 |
Dec 8, 1993 |
|
|
|
Current U.S.
Class: |
544/405 ;
544/238; 544/333; 546/281.7; 548/525; 549/510 |
Current CPC
Class: |
C07D 305/14
20130101 |
Class at
Publication: |
544/405 ;
549/510; 546/281.7; 548/525; 544/238; 544/333 |
International
Class: |
C07D 45/02; C07D
35/14 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 9, 1992 |
FR |
92 14813 |
Claims
1. A taxoid of the formula: 36in which R represents an alkoxyacetyl
radical, R.sub.1 represents a benzoyl radical or a radical
R.sub.2--O--CO in which R.sub.2 represents an alkyl, alkenyl,
alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or
heterocyclyl radical, and Ar represents an aryl radical:
2. The taxoid according to claim 1, wherein: R represents an
alkoxyacetyl radical, R.sub.1 represents a benzoyl radical or a
radical R.sub.2--O--CO in which R.sub.2 represents: a straight or
branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl
radical containing 2 to 8 carbon atoms, an alkynyl radical
containing 3 to 8 carbon atoms, a cycloalkyl radical containing 3
to 6 carbon atoms, a cycloalkenyl radical containing 4 to 6 carbon
atoms or a bicycloalkyl radical containing 7 to 10 carbon atoms,
these radicals being optionally substituted by one or more
substituents, which are identical or different, chosen from halogen
atoms and hydroxy radicals, alkoxy radicals containing 1 to 4
carbon atoms, dialkylamino radicals in which each alkyl portion
contains 1 to 4 carbon atoms, piperidino radicals, morpholino
radicals, 1-piperazinyl radicals (optionally substituted at
position 4 by an alkyl radical containing 1 to 4 carbon atoms or by
a phenylalkyl radical whose alkyl portion contains 1 to 4 carbon
atoms), cycloalkyl radicals containing 3 to 6 carbon atoms,
cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl
radicals, cyano radicals, carboxy radicals and alkoxycarbonyl
radicals whose alkyl portion contains 1 to 4 carbon atoms, or a
phenyl radical optionally substituted by one or more radicals,
which are identical or different, chosen from alkyl radicals
containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to
4 carbon atoms, or a saturated or unsaturated 5- or 6-membered
nitrogen-containing heterocyclyl radical optionally substituted by
one or more alkyl radicals containing 1 to 4 carbon atoms, it being
understood that the cycloalkyl, cycloalkenyl or bicycloalkyl
radicals may be optionally substituted by one or more alkyl
radicals containing 1 to 4 carbon atoms, and Ar represents a phenyl
or .alpha.- or .beta.-naphthyl radical optionally substituted by
one or more atoms or radicals, chosen from halogen atoms (fluorine,
chlorine, bromine, or iodine) and alkyl, alkenyl, alkynyl, aryl,
arylalkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxy,
hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino,
alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxy,
alkoxycarbonyl, carbamoyl, dialkylcarbamoyl, cyano, nitro and
trifluoromethyl radicals, it being understood that the alkyl
radicals and the alkyl portions of the other radicals contain 1 to
4 carbon atoms, that the alkenyl and alkynyl radicals contain 2 to
8 carbon atoms and that the aryl radicals are phenyl or .alpha.- or
.beta.-naphthyl radicals or alternatively Ar represents a
5-membered aromatic heterocyclic radical containing one or more
hetero atoms, which are identical or different, chosen from
nitrogen, oxygen or sulphur atoms, optionally substituted by one or
more substituents, which are identical or different, chosen from
halogen atoms (fluorine, chlorine, bromine or iodine) and alkyl
radicals containing 1 to 4 carbon atoms, aryl radicals containing 6
to 10 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms,
aryloxy radicals containing 6 to 10 carbon atoms, amino radicals,
alkylamino radicals containing 1 to 4 carbon atoms, dialkylamino
radicals in which each alkyl portion contains 1 to 4 carbon atoms,
acylamino radicals in which the acyl portion contains 1 to 4 carbon
atoms, alkoxycarbonylamino radicals containing 1 to 4 carbon atoms,
acyl radicals containing 1 to 4 carbon atoms, arylcarbonyl radicals
in which the aryl portion contains 6 to 10 carbon atoms, cyano
radicals, carboxy radicals, carbamoyl radicals, alkylcarbamoyl
radicals in which the alkyl portion contains 1 to 4 carbon atoms,
dialkylcarbamoyl radicals in which each alkyl portion contains 1 to
4 carbon atoms and alkoxycarbonyl radicals in which the alkoxy
portion contains 1 to 4 carbon atoms.
3. The taxoid according to claim 1, wherein R.sub.1 represents a
benzoyl radical.
4. The taxoid according to claim 1, wherein R.sub.1 represents a
benzoyl radical and Ar represents a phenyl radical.
5. A process for the preparation of a taxoid of claim 1 comprising
esterifying a product of the formula: 37in which G.sub.1 represents
an alkoxyacetyl radical or other hydroxy-protecting group, with a
free acid of the formula: 38or a derivative of the free acid
capable of being converted into the free acid, in which Ar and
R.sub.1 are defined as in claim 1, R.sub.3 represents a hydrogen
atom or an alkoxy radical containing 1 to 4 carbon atoms or an
optionally substituted aryl radical and R.sub.4 represents a
hydrogen atom, to give a product of the formula: 39in which Ar, R
and R.sub.1 are defined as in claim 1, R.sub.3, R.sub.4, and
G.sub.1 are defined as above, treating this product in acidic
medium to give a product of the formula: 40in which Ar, R.sub.1 and
G.sub.1, are defined as above, and then optionally replacing the
protecting group G.sub.1 by a hydrogen atom or an alkoxyacetyl
radical, said alkoxyacetyl radical being obtained by action of an
alkoxyacetic acid or derivative thereof on a compound obtained
after replacement of G.sub.1 by a hydrogen atom, and isolating the
product obtained.
6. The process according to claim 5, wherein the esterification is
carried out by means of the free acid, the procedure being carried
out in the presence of a condensing agent chosen from carbodiimides
and reactive carbonates and an activating agent chosen from
aminopyridines in an organic solvent chosen from ethers, ketones,
esters, nitrites, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons and aromatic hydrogens at a temperature ranging from
-10 to 90.degree. C.
7. The process according to claim 5, wherein the esterification by
means of an anhydride derivative of the free acid is carried out in
the presence of an activating agent chosen from aminopyridines in
an organic solvent chosen from ethers, esters, ketones, nitrites,
aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and
aromatic hydrocarbons at a temperature ranging from 0 to 90.degree.
C.
8. The process according to claim 5, wherein the esterification is
carried out by means of a halide or anhydride derivative of the
free acid with an aliphatic or aromatic acid, optionally prepared
in situ, the procedure being carried out in the presence of a base
chosen from tertiary aliphatic amines in an organic solvent chosen
from ethers, esters, ketones, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from 0 to 80.degree. C.
9. The process according to claim 5, wherein the acid treatment is
carried out by means of an inorganic or organic acid in an organic
solvent at a temperature ranging from -10 to 60.degree. C.
10. The process according to claim 9, wherein the acid is chosen
from hydrochloric, sulphuric, acetic, methanesulphonic,
trifluoromethanesulphonic and p-toluenesulphonic acids, used alone
or in the form of a mixture.
11. The process according to claim 9, wherein the solvent is chosen
from alcohols, ethers, esters, halogenated aliphatic hydrocarbons,
aromatic hydrocarbons and nitrites.
12. The process according to claim 5, wherein the replacement by a
hydrogen atom of the protecting group G.sub.1, when G.sub.1
represents a 2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radical, is carried out by
treatment using zinc, optionally combined with copper, in the
presence of acetic acid at a temperature ranging from 30 to
60.degree. C. or by means of an inorganic or organic acid selected
from hydrochloric acid or acetic acid in solution in an aliphatic
alcohol containing 1 to 3 carbon atoms or an aliphatic ester
selected from ethyl acetate, isopropyl acetate and n-butyl acetate
in the presence of zinc optionally combined with copper, and, when
G.sub.1 represents an alkoxyacetyl radical, by treatment in
alkaline medium by means of ammonia in aqueous-alcoholic medium at
a temperature close to 20.degree. C. or by treatment using a zinc
halide in methanol at a temperature close to 20.degree. C.
13. A process for the preparation of a taxoid according to claim 1
comprising esterifying a product of the formula: 41in which G.sub.1
represents an alkoxyacetyl radical or other hydroxy-protecting
group, by means of a free acid of the formula: 42or a derivative of
the free acid capable of being converted into the free acid, in
which Ar and R.sub.1 are defined as in claim 1, and R.sub.3 and
R.sub.4, which are identical or different, represent an alkyl
radical containing 1 to 4 carbon atoms or an aralkyl radical whose
alkyl portion contains 1 to 4 carbon atoms or an aryl radical, or
alternatively R.sub.3 represents a trihalomethyl radical or a
phenyl radical substituted by a trihalomethyl radical and R.sub.4
represents a hydrogen atom, or alternatively R.sub.3 and R.sub.4
form, together with the carbon atom to which they are attached, a
4- to 7-membered ring, to give, after treating in acidic medium, a
product of the formula: 43in which Ar is defined as in claim 1, and
G.sub.1 is defined as above, and acylating the product by means of
benzoyl chloride or a reactive derivative of the
formula:R.sub.2--O--CO--Xin which R.sub.2 is defined as in claim 1
and X represents a halogen atom or a residue --O--R.sub.2 or
--O--CO--O--R.sub.2, in which R.sub.2 is defined as in claim 1, and
then replacing the protecting group G.sub.1, if necessary, by a
hydrogen atom or an alkoxyacetyl radical, said alkoxyacetyl radical
being obtained by action of an alkoxyacetic acid or derivative
thereof on a compound obtained after replacement of G.sub.1 by a
hydrogen atom, and isolating the product obtained.
14. The process according to claim 13, wherein the esterification
is carried out by means of the free acid, the procedure being
carried out in the presence of a condensing agent chosen from
carbodiimides and reactive carbonates and an activating agent
chosen from aminopyridines in an organic solvent chosen from
ethers, ketones, esters, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from -10 to 90.degree. C.
15. The process according to claim 13, wherein the esterification
by means of an anhydride derivative of the free acid is carried out
in the presence of an activating agent chosen from aminopyridines
in an organic solvent chosen from ethers, esters, ketones,
nitrites, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons and aromatic hydrocarbons at a temperature ranging
from 0 to 90.degree. C.
16. The process according to claim 13, wherein the esterification
is carried out by means of a halide or anhydride derivative of the
free acid with an aliphatic or aromatic acid, optionally prepared
in situ, the procedure being carried out in the presence of a base
chosen from tertiary aliphatic amines in an organic solvent chosen
from ethers, esters, ketones, nitriles, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from 0 to 80.degree. C.
17. The process according to claim 13, wherein the acid treatment
is carried out by means of an inorganic or organic acid in an
organic solvent at a temperature ranging from 0 to 50.degree.
C.
18. The process according to claim 17, wherein the acid is chosen
from hydrochloric, sulphuric and formic acids.
19. The process according to claim 17, wherein the solvent is
chosen from alcohols containing 1 to 3 carbon atoms.
20. The process according to claim 13, wherein the acylation is
carried out in an inert organic solvent in the presence of an
inorganic or organic base.
21. The process according to claim 20, wherein the inert organic
solvent is chosen from esters and halogenated aliphatic
hydrocarbons.
22. The process according to claim 16, wherein the procedure is
carried out at a temperature ranging from 0 to 50.degree. C.
23. The process according to claim 13, wherein the replacement by a
hydrogen atom of the protecting group G.sub.1, when it represents a
2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radical, is carried out by
treatment using zinc, optionally combined with copper, in the
presence of acetic acid at a temperature ranging from 30 to
60.degree. C. or by means of an inorganic or organic acid selected
from hydrochloric acid or acetic acid in solution in an aliphatic
alcohol containing 1 to 3 carbon atoms or an aliphatic ester
selected from ethyl acetate, isopropyl acetate and n-butyl acetate
in the presence of zinc optionally combined with copper, or, when
it represents an alkoxy acetyl radical, by treatment in alkaline
medium by means of ammonia in aqueous-alcoholic medium at a
temperature close to 20.degree. C. or by treatment using a zinc
halide in methanol at a temperature close to 20.degree. C.
24. A process for the preparation of a taxoid according to claim 1,
comprising esterifying a product of the formula: 44in which G.sub.1
represents a hydroxy-protecting group, by means of a free acid of
the formula: 45or a derivative of the free acid capable of being
converted into the free acid, in which Ar and R.sub.1 are defined
as in claim 1 and G.sub.3 represents a hydroxy-protecting group, or
of an activated derivative of this acid, to give a product of the
formula: 46in which Ar, R.sub.1, G.sub.1 and G.sub.3 are defined as
above, replacing the protecting groups G.sub.3 and optionally
G.sub.1 by a hydrogen atom or an alkoxyacetyl radical, said
alkoxyacetyl radical being obtained by action of an alkoxyacetic
acid or derivative thereof on a compound obtained after replacement
of G.sub.1 by a hydrogen atom, and isolating the product
obtained.
25. The process according to claim 24, wherein the esterification
is carried out by means of the free acid, the procedure being
carried out in the presence of a condensing agent chosen from
carbodiimides and reactive carbonates and an activating agent
chosen from aminopyridines in an organic solvent chosen from
ethers, ketones, esters, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from -10 to 90.degree. C.
26. The process according to claim 24, wherein the esterification
by means of an anhydride derivative of the free acid is carried out
in the presence of an activating agent chosen from aminopyridines
in an organic solvent chosen from ethers, esters, ketones,
nitrites, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons and aromatic hydrocarbons at a temperature ranging
from 0 to 90.degree. C.
27. The process according to claim 24, wherein the esterification
is carried out by means of a halide or anhydride derivative of the
free acid with an aliphatic or aromatic acid, optionally prepared
in situ, the procedure being carried out in the presence of a base
chosen from tertiary aliphatic amines in an organic solvent chosen
from ethers, esters, ketones, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from 0 to 80.degree. C.
28. The process according to claim 24, wherein the replacement of
the protecting groups G.sub.1 and G.sub.3 by hydrogen atoms is
carried out by treatment with zinc, optionally combined with
copper, in the presence of acetic acid at a temperature ranging
from 30 to 60.degree. C. or by means of an inorganic or organic
acid selected from hydrochloric acid or acetic acid in solution in
an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic
ester selected from ethyl acetate, isopropyl acetate and n-butyl
acetate in the presence of zinc, optionally combined with copper,
when G.sub.1 and G.sub.3 represent a 2,2,2-trichloroethoxycarbonyl
or 2-(2-trichloromethylpropoxy)carbonyl radical, or by treatment in
acidic medium selected from hydrochloric acid in solution in an
aliphatic alcohol containing 1 to 3 carbon atoms (methanol,
ethanol, propanol or isopropanol) or aqueous hydrofluoric acid at a
temperature ranging from 0 to 40.degree. C. when G.sub.3 represents
a silylated radical or an acetal residue, followed by the
replacement of the protecting group G.sub.1 by treatment using
zinc, optionally combined with copper, in the presence of acetic
acid at a temperature ranging from 30 to 60.degree. C. or by means
of an inorganic or organic acid selected from hydrochloric acid or
acetic acid in solution in an aliphatic alcohol containing 1 to 3
carbon atoms or an aliphatic ester selected from ethyl acetate,
isopropyl acetate or n-butyl acetate in the presence of zinc
optionally combined with copper, or, when G.sub.1 represents an
alkoxyacetyl radical, by treatment in alkaline medium by means of
ammonia in aqueous-alcoholic medium at a temperature close to
20.degree. C. or by treatment using a zinc halide in methanol at a
temperature close to 20.degree. C.
29. The process according to claim 24, wherein when G.sub.3
represents a radical --CH.sub.2--Ph, the replacement of the group
by a hydrogen atom is carried out by hydrogenolysis, after
replacing the protecting group G.sub.1.
30. A taxoid of the formula: 47in which G.sub.1 represents an
alkoxyacetyl radical or other hydroxy-protecting group.
31. A pharmaceutical composition comprising at least one product
according to claim 1, in combination with one or more
pharmaceutically acceptable, inert or physiologically active,
products.
32. A method for treating mammalian tumors comprising administering
to a mammal an effective amount of at least one compound according
to claim 1.
33. A method for treating a pathological condition in a host
wherein said pathological condition is associated with abnormal
cell proliferation said method comprising administering to said
host an effective amount of at least one compound according to
claim 1.
34. A method according to claim 33, wherein the abnormal cells are
malignant cells.
35. A method according to claim 33, wherein the abnormal cells are
non-malignant.
36. A method according to claim 34, wherein said pathological
condition comprises abnormal cellular proliferation of malignant or
non-malignant cells or various tissues and/or organs including,
muscle, bone or connective tissues, skin, brain, lungs, sex organs,
lymphatic or renal systems, mammary or blood cells, liver,
digestive tract, pancreas and thyroid or adrenal glands.
37. A method according to claim 33, wherein the pathological
condition is psoriasis, solid tumors, cancer of the ovary, breast,
brain, prostate, colon, stomach, kidney or testicles, Kaposi's
sarcoma, cholangioma, chorioma, neuroblastoma, Wilms' tumor,
Hodgkin's disease, melanomas, multiple myelomas, lymphatic
leukemia, and acute or chronic granulocytic lymphomas.
38. A method according to claim 33, wherein the pathological
condition is ovarian cancer.
39. A method according to claim 32, wherein the treatment is
performed concurrently with at least one other therapeutic
treatment.
40. A method according to claim 39, wherein the other therapeutic
treatment comprises antineoplastic drugs, monoclonal antibodies,
immunotherapies, radiotherapies, or biological response
modifiers.
41. A method according to claim 40, wherein the response modifiers
comprise lymphokines and cytokines, including interleukins,
interferons (.alpha., .beta., or .delta.) and TNF.
42. A method according to claim 40, wherein the antineoplastic
drugs comprise alkylating agents, including nitrogen mustards
selected from mechlorethamine, cyclophosphamide, melphalan and
chlorambucil; alkyl sulphates selected from busulfan; nitrosoureas
selected from carmustine, lomustine, semustine and streptozoci;
triazenes selected from dacarbazine; antimetabolites selected from
folic acid analogues including methotrexate; pyrimidine analogues
selected from fluorouracil and cytarabine; and purine analogues
selected from mercaptopurine and thioguanine; natural products
including vinca alkaloids selected from vinblastine, vincristine
and vindesine; epipodophyllotoxins selected from etoposide and
teniposid;, antibiotics selected from dactinomycin, daunorubicin,
doxorubincin, bleomycin, plicamycin and mitomycin; enzymes selected
from L-asparaginase; various agents selected from coordination
complexes of platinum including cisplatin; substituted ureas
including hydroxyurea; methylhydrazine derivatives selected from
procarbazine; adrenocortical suppressants selected from mitotane
and aminoglutethymide; hormones and antagonists selected from
adrenocorticosteroids selected from prednisone; progestins selected
from hydroxyprogesterone caproate, methoxyprogesterone acetate and
megestrol acetate; oestrogens selected from diethylstilbestrol and
ethynylestradiol; antiestrogens selected from tamoxifen; and
androgens selected from testosterone propionate and
fluoroxymesterone.
43. A pharmaceutical composition according to claim 31, wherein the
composition is suitable for parenteral administration.
44. A pharmaceutical composition according to claim 43, wherein the
composition is suitable for intravenous, intraperitoneal,
intramuscular or subcutaneous administration.
45. A pharmaceutical composition according to claim 31, comprising
pharmaceutically acceptable adjuvants, carriers or excipients.
46. A pharmaceutical composition according to claim 45, wherein the
adjuvant, carrier or excipient is selected from a diluent, sterile
aqueous media and non-toxic solvents.
47. A pharmaceutical composition according to claim 31, wherein the
composition is an aqueous solution, an aqueous suspension, or an
injectable solution.
48. A pharmaceutical composition according to claim 47, wherein the
composition comprises at least one emulsifying agent, colorant,
preservative or stabilizer.
49. A pharmaceutical composition according to claim 43, wherein the
composition is an aqueous or non-aqueous solution or
suspension.
50. A taxoid of the formula: 48in which R represents an
alkoxyacetyl radical, R.sub.1 represents a radical R.sub.2--O--CO--
in which R.sub.2 represents an alkyl radical, and Ar represents an
aryl radical.
51. A taxoid according to claim 50, wherein: R represents an
alkoxyacetyl radical, R.sub.1 represents a radical R.sub.2--O--CO
in which R.sub.2 represents: a straight or branched alkyl radical
containing 1 to 8 carbon atoms optionally substituted by one or
more substituents, which are identical or different, chosen from
halogen atoms and hydroxy radicals; alkoxy radicals containing 1 to
4 carbon atoms; dialkylamino radicals in which each alkyl portion
contains 1 to 4 carbon atoms; piperidino radicals; morpholino
radicals; 1-piperazinyl radicals (optionally substituted at
position 4 by an alkyl radical containing 1 to 4 carbon atoms or by
a phenylalkyl radical whose alkyl portion contains 1 to 4 carbon
atoms); cycloalkyl radicals containing 3 to 6 carbon atoms;
cycloalkenyl radicals containing 4 to 6 carbon atoms; phenyl
radicals; cyano radicals; carboxy radicals or alkoxycarbonyl
radicals whose alkyl portion contains 1 to 4 carbon atoms, Ar
represents a phenyl or .alpha.- or .beta.-naphthyl radical
optionally substituted by one or more atoms or radicals, chosen
from halogen atoms (fluorine, chlorine, bromine, or iodine) and
alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy, alkylthio,
aryloxy, arylthio, hydroxy, hydroxyalkyl, mercapto, formyl, acyl,
acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino,
dialkylamino, carboxy, alkoxycarbonyl, carbamoyl, dialkylcarbamoyl,
cyano, nitro and trifluoromethyl radicals, it being understood that
the alkyl radicals and the alkyl portions of the other radicals
contain 1 to 4 carbon atoms, that the alkenyl and alkynyl radicals
contain 2 to 8 carbon atoms and that the aryl radicals are phenyl
or .alpha.- or .beta.-naphthyl radicals or alternatively Ar
represents a 5-membered aromatic heterocyclic radical containing
one or more hetero atoms, which are identical or different, chosen
from nitrogen, oxygen or sulphur atoms, optionally substituted by
one or more substituents, which are identical or different, chosen
from halogen atoms (fluorine, chlorine, bromine or iodine) and
alkyl radicals containing 1 to 4 carbon atoms, aryl radicals
containing 6 to 10 carbon atoms, alkoxy radicals containing 1 to 4
carbon atoms, aryloxy radicals containing 6 to 10 carbon atoms,
dialkylamino radicals in which each alkyl portion contains 1 to 4
carbon atoms, acylamino radicals in which the acyl portion contains
1 to 4 carbon atoms, alkoxycarbonylamino radicals containing 1 to 4
carbon atoms, acyl radicals containing 1 to 4 carbon atoms,
arylcarbonyl radicals in which the aryl portion contains 6 to 10
carbon atoms, cyano radicals, carboxy radicals, carbamoyl radicals,
alkylcarbamoyl radicals in which the alkyl portion contains 1 to 4
carbon atoms, dialkylcarbamoyl radicals in which each alkyl portion
contains 1 to 4 carbon atoms or alkoxycarbonyl radicals in which
the alkoxy portion contains 1 to 4 carbon atoms.
52. A taxoid according to claim 50, wherein R represents an
alkoxyacetyl radical, R.sub.1 represents a radical R.sub.2--O--CO--
in which R.sub.2 represents a t-butyl radical and Ar represents an
aryl radical.
53. A taxoid according to claim 50, wherein R.sub.1 represents a
radical R.sub.2--O--CO in which R.sub.2 represents a t-butyl
radical and Ar represents a phenyl radical.
54. A process for the preparation of a taxoid according to claim
50, comprising esterifying a product of the formula: 49in which
G.sub.1 represents an alkoxyacetyl radical or other
hydroxy-protecting group, with a free acid of the formula: 50or a
derivative of the free acid capable of being converted into the
free acid, in which Ar and R.sub.1 are defined as in claim 50,
R.sub.3 represents a hydrogen atom or an alkoxy radical containing
1 to 4 carbon atoms or an optionally substituted aryl radical and
R.sub.4 represents a hydrogen atom, to give a product of the
formula: 51in which Ar, R and R.sub.1 are defined as in claim 50,
R.sub.3, R.sub.4 and G.sub.1 are defined as above, treating this
product in acidic medium to give a product of the formula: 52in
which Ar, R.sub.1 and G.sub.1 are defined as above, and then
optionally replacing the protecting group G.sub.1 by a hydrogen
atom or an alkoxyacetyl radical, said alkoxyacetyl radical being
obtained by action of an alkoxyacetic acid or derivative thereof on
a compound obtained after replacement of G.sub.1 by a hydrogen
atom, and isolating the product obtained.
55. The process according to claim 54, wherein the esterification
is carried out by means of the free acid, the procedure being
carried out in the presence of a condensing agent chosen from
carbodiimides and reactive carbonates and an activating agent
chosen from aminopyridines in an organic solvent chosen from
ethers, ketones, esters, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from -10 to 90.degree. C.
56. The process according to claim 54, wherein the esterification
by means of an anhydride derivative of the free acid is carried out
in the presence of an activating agent chosen from aminopyridines
in an organic solvent chosen from ethers, esters, ketones,
nitriles, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons and aromatic hydrocarbons at a temperature ranging
from 0 to 90.degree. C.
57. The process according to claim 54; wherein the esterification
is carried out by means of a halide or anhydride derivative of the
free acid with an aliphatic or aromatic acid, optionally prepared
in situ, the procedure being carried out in the presence of a base
chosen from tertiary aliphatic amines in an organic solvent chosen
from ethers, esters, ketones, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from 0 to 80.degree. C.
58. The process according to claim 54, wherein the acid treatment
is carried out by means of an inorganic or organic acid in an
organic solvent at a temperature ranging from -10 to 60.degree.
C.
59. The process according to claim 57, wherein the acid is chosen
from hydrochloric, sulphuric, acetic, methanesulphonic,
trifluoromethanesulphonic and p-toluenesulphonic acids, used alone
or in the form of a mixture.
60. The process according to claim 57, wherein the solvent is
chosen from alcohols, ethers, esters, halogenated aliphatic
hydrocarbons, aromatic hydrocarbons and nitriles.
61. The process according to claim 54, wherein the replacement by a
hydrogen atom of the protecting group G.sub.1, when it represents a
2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radical, is carried out by
treatment using zinc, optionally combined with copper, in the
presence of acetic acid at a temperature ranging from 30 to
60.degree. C. or by means of an inorganic or organic acid selected
from hydrochloric acid or acetic acid in solution in an aliphatic
alcohol containing 1 to 3 carbon atoms or an aliphatic ester
selected from ethyl acetate, isopropyl acetate or n-butyl acetate
in the presence of zinc optionally combined with copper, and, when
it represents an alkoxyacetyl radical, by treatment in alkaline
medium by means of ammonia in aqueous-alcoholic medium at a
temperature close to 20.degree. C. or by treatment using a zinc
halide in methanol at a temperature close to 20.degree. C.
62. A process for the preparation of a taxoid according to claim
50, comprising esterifying a product of the formula: 53in which
G.sub.1 represents an alkoxyacetyl radical or other
hydroxy-protecting group, by means of a free acid of the formula:
54or a derivative of the free acid capable of being converted into
the free acid, in which Ar and R.sub.1 are defined as in claim 50
and R.sub.3 and R.sub.4, which are identical or different,
represent an alkyl radical containing 1 to 4 carbon atoms or an
aralkyl radical whose alkyl portion contains 1 to 4 carbon atoms or
an aryl radical, or alternatively R.sub.3 represents a
trihalomethyl radical or a phenyl radical substituted by a
trihalomethyl radical and R.sub.4 represents a hydrogen atom, or
alternatively R.sub.3 and R.sub.4 form, together with the carbon
atom to which they are attached, a 4- to 7-membered ring, to give,
after treating in acidic medium, a product of the formula: 55in
which Ar is defined as in claim 50 and G.sub.1 is defined as above,
and acylating the product by means of benzoyl chloride or a
reactive derivative of the formula:R.sub.2 --O--CO--Xin which
R.sub.2 is defined as in claim 50 and X represents a halogen atom
or a residue --O--R.sub.2 or --O--CO--O--R.sub.2, and then
replacing the protecting group G.sub.1, if necessary, by a hydrogen
atom or an alkoxyacetyl radical, said alkoxyacetyl radical being
obtained by action of an alkoxyacetic acid or derivative thereof on
a compound obtained after replacement of G.sub.1 by a hydrogen
atom, and isolating the product obtained.
63. The process according to claim 62, wherein the esterification
is carried out by means of the free acid, the procedure being
carried out in the presence of a condensing agent chosen from
carbodiimides and reactive carbonates and an activating agent
chosen from aminopyridines in an organic solvent chosen from
ethers, ketones, esters, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from -10 to 90.degree. C.
64. The process according to claim 62, wherein the esterification
by means of an anhydride derivative of the free acid is carried out
in the presence of an activating agent chosen from aminopyridines
in an organic solvent chosen from ethers, esters, ketones,
nitrites, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons and aromatic hydrocarbons at a temperature ranging
from 0 to 90.degree. C.
65. The process according to claim 62, wherein the esterification
is carried out by means of a halide or anhydride derivative of the
free acid with an aliphatic or aromatic acid, optionally prepared
in situ, the procedure being carried out in the presence of a base
chosen from tertiary aliphatic amines in an organic solvent chosen
from ethers, esters, ketones, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from 0 to 80.degree. C.
66. The process according to claim 62, wherein the acid treatment
is carried out by means of an inorganic or organic acid in an
organic solvent at a temperature ranging from 0 to 50.degree.
C.
67. The process according to claim 66, wherein the acid is chosen
from hydrochloric, sulphuric and formic acids.
68. The process according to claim 66, wherein the solvent is
chosen from alcohols containing 1 to 3 carbon atoms.
69. The process according to claim 62, wherein the acylation is
carried out in an inert organic solvent in the presence of an
inorganic or organic base.
70. The process according to claim 69, wherein the inert organic
solvent is chosen from esters and halogenated aliphatic
hydrocarbons.
71. The process according to claim 65, wherein the procedure is
carried out at a temperature ranging from 0 and 50.degree. C.
72. The process according to claim 62, wherein the replacement by a
hydrogen atom of the protecting group G.sub.1, when it represents a
2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radical, is carried out by
treatment using zinc, optionally combined with copper, in the
presence of acetic acid at a temperature ranging from 30 to
60.degree. C. or by means of an inorganic or organic acid selected
from hydrochloric acid or acetic acid in solution in an aliphatic
alcohol containing 1 to 3 carbon atoms or an aliphatic ester
selected from ethyl acetate, isopropyl acetate or n-butyl acetate
in the presence of zinc optionally combined with copper, or, when
it represents an alkoxy acetyl radical, by treatment in alkaline
medium by means of ammonia in aqueous-alcoholic medium at a
temperature close to 20.degree. C. or by treatment using a zinc
halide in methanol at a temperature close to 20.degree. C.
73. A process for the preparation of a taxoid according to claim
50, comprising esterifying a product of the formula: 56in which
G.sub.1 represents a hydroxy-protecting group, by means of a free
acid of the formula: 57or a derivative of the free acid capable of
being converted into the free acid, in which Ar and R.sub.1 are
defined as in claim 50 and G.sub.3 represents a hydroxy-protecting
group, or of an activated derivative of this acid, to give a
product of the formula: 58in which Ar, R.sub.1, G.sub.1 and G.sub.3
are defined as above, replacing the protecting groups G.sub.3 and
optionally G.sub.1 by a hydrogen atom or an alkoxyacetyl radical,
said alkoxyacetyl radical being obtained by action of an
alkoxyacetic acid or derivative thereof on a compound obtained
after replacement of G.sub.1 by a hydrogen atom, and isolating the
product obtained.
74. The process according to claim 73, wherein the esterification
is carried out by means of the free acid, the procedure being
carried out in the presence of a condensing agent chosen from
carbodiimides and reactive carbonates and an activating agent
chosen from aminopyridines in an organic solvent chosen from
ethers, ketones, esters, nitriles, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from -10 to 90.degree. C.
75. The process according to claim 73, wherein the esterification
by means of an anhydride derivative of the free acid is carried out
in the presence of an activating agent chosen from aminopyridines
in an organic solvent chosen from ethers, esters, ketones,
nitriles, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons and aromatic hydrocarbons at a temperature ranging
from 0 to 90.degree. C.
76. The process according to claim 73, wherein the esterification
is carried out by means of a halide or an anhydride derivative of
the free acid with an aliphatic or aromatic acid, optionally
prepared in situ, the procedure being carried out in the presence
of a base chosen from tertiary aliphatic amines in an organic
solvent chosen-from ethers, esters, ketones, nitriles, aliphatic
hydrocarbons, halogenated aliphatic hydrocarbons and aromatic
hydrocarbons at a temperature ranging from 0 to 80.degree. C.
77. The process according to claim 73, wherein the replacement of
the protecting groups G.sub.1 and G.sub.3 by hydrogen atoms is
carried out by treatment with zinc, optionally combined with
copper, in the presence of acetic acid at a temperature ranging
from 30 to 60.degree. C. or by means of an inorganic or organic
acid selected from hydrochloric acid or acetic acid in solution in
an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic
ester selected from ethyl acetate, isopropyl acetate or n-butyl
acetate in the presence of zinc optionally combined with copper,
when G.sub.1 and G.sub.3 represent a 2,2,2-trichloroethoxycarbonyl
or 2-(2-trichloromethylpropoxy)carbonyl radical, or by treatment in
acidic medium selected from for example hydrochloric acid in
solution in an aliphatic alcohol containing 1 to 3 carbon atoms
(methanol, ethanol, propanol or isopropanol) or aqueous
hydrofluoric acid at a temperature ranging from 0 to 40.degree. C.
when G.sub.3 represents a silylated radical or an acetal residue,
followed by the replacement of the protecting group G.sub.1 by
treatment using zinc, optionally combined with copper, in the
presence of acetic acid at a temperature ranging from 30 to
60.degree. C. or by means of an inorganic or organic acid selected
from hydrochloric acid or acetic acid in solution in an aliphatic
alcohol containing 1 to 3 carbon atoms or an aliphatic ester
selected from ethyl acetate, isopropyl acetate or n-butyl acetate
in the presence of zinc optionally combined with copper, or, when
G.sub.1 represents an alkoxyacetyl radical, by treatment in
alkaline medium by means of ammonia in aqueous-alcoholic medium at
a temperature close to 20.degree. C. or by treatment using a zinc
halide in methanol at a temperature close to 20.degree. C.
78. The process according to claim 73, wherein when G.sub.3
represents a radical --CH.sub.2--Ph, the replacement of the group
by a hydrogen atom is carried out by hydrogenolysis, after
replacing the protecting group G.sub.1.
79. A pharmaceutical composition comprising at least one product
according to claim 50 in combination with one or more
pharmaceutically acceptable, inert or physiologically active,
products.
80. A method for treating mammalian tumors comprising administering
to a mammal an effective amount of at least one compound according
to claim 50.
81. A method for treating a pathological condition in a host
wherein said pathological condition is associated with abnormal
cell proliferation said method comprising administering to said
host an effective amount of at least one compound according to
claim 50.
82. A method according to claim 81, wherein the abnormal cells are
malignant cells.
83. A method according to claim 81, wherein the abnormal cells are
non-malignant.
84. A method according to claim 82, wherein said pathological
condition comprises abnormal cellular proliferation of malignant or
non-malignant cells of various tissues and/or organs including,
muscle, bone or connective tissues, skin, brain, lungs, sex organs,
lymphatic or renal systems, mammary or blood cells, liver,
digestive tract, pancreas and thyroid or adrenal glands.
85. A method according to claim 81, wherein the pathological
condition is psoriasis, solid tumors, cancer of the ovary, breast,
brain, prostate, colon, stomach, kidney or testicles, Kaposi's
sarcoma, cholangioma, chorioma, neuroblastoma, Wilms' tumor,
Hodgkin's disease, melanomas, multiple myelomas, lymphatic
leukaemia, and acute or chronic granulocytic lymphomas.
86. A method according to claim 81, wherein the pathological
condition is ovarian cancer.
87. A method according to any one of claim 80, wherein the
treatment is performed concurrently with at least one other
therapeutic treatment.
88. A method according to claim 87, wherein the other therapeutic
treatment comprises antineoplastic drugs, monoclonal antibodies,
immunotherapies, radiotherapies,or biological response
modifiers.
89. A method according to claim 88, wherein the response modifiers
comprise lymphokines and cytokines, including interleukins,
interfeons (.alpha., .beta. or .delta.) and TNF.
90. A method according to claim 88, wherein the antineoplastic
drugs comprise alkylating agents like nitrogen mustards selected
from mechlorethamine, cyclophosphamide, melphalan and chlorambucil,
alkyl sulphates selected from busulfan, nitrosoureas selected from
carmustine, lomustine, semustine and streptozocin, triazenes
selected from dacarbazine, antimetabolites selected from folic
analogies like methotrexate, pyrimidine analogues selected from
fluorouracil and cytarabine, purine analogues selected from
mercaptopurine and thioguanine, natural products like vinca
alkaloids selected from vinblastine, vincristine and vindesine,
epipodophyllotoxins selected from etoposide and teniposide,
antibiotics selected from dactinomycin, daunorubicin, doxorubincin,
bleomycin, plicamycin and mitomycin, enzymes selected from
L-asparaginase, various agents selected from coordination complexes
of platinum like cisplatin, substituted ureas like hydroxyurea,
methylhydrazine derivatives selected from procarbazine,
adrenocortical suppressants selected from mitotane and
aminoglutethymide, hormones and antagonists selected from
adrenocorticosteroids selected from prednisone, progestins selected
from hydroxyprogesterone caproate, methoxyprogesterone acetate and
megestrol acetate, oestrogens selected from diethylstilbestrol and
ethynylestradiol, antiestrogens selected from tamoxifen, and
androgens selected from testosterone propionate and
fluoxymesterone.
91. A pharmaceutical composition according to claim 79, wherein the
composition is suitable for parenteral administration.
92. A pharmaceutical composition according to claim 91, wherein the
composition is suitable for intravenous, intraperitoneal,
intramuscular or subcutaneous administration.
93. A pharmaceutical composition according to claim 79, comprising
a pharmaceutically acceptable adjuvants, carriers or
excipients.
94. A pharmaceutical composition according to claim 93, wherein the
adjuvant, carrier or excipient is selected from a diluent, sterile
aqueous media and non-toxic solvents.
95. A pharmaceutical composition according to claim 79, wherein the
composition is an aqueous solution, an aqueous suspension, or an
injectable solution.
96. A pharmaceutical composition according to claim 95, wherein the
composition comprises at least one emulsifying agent, colorant,
preservative or stabilizer.
97. A pharmaceutical composition according to claim 91, wherein the
composition is an aqueous or non-aqueous solution or
suspension.
98. The taxoid of claim 1, wherein the alkoxy portion of the
alkoxyacetyl radical contains 1 to 8 carbon atoms.
99. The taxoid of claim 50, wherein the alkoxy portion of the
alkoxyacetyl radical contains 1 to 8 carbon atoms.
100. The taxoid of claim 50, wherein R represents methoxyacetyl,
R.sub.2 represents a t-butyl radical, and Ar represents
thienyl.
101. The taxoid of claim 50, wherein R represents methoxyacetyl,
R.sub.2 represents a t-butyl radical, and Ar represents phenyl.
102. The taxoid of claim 50, wherein R represents butoxyacetyl,
R.sub.2 represents a t-butyl radical, and Ar represents phenyl.
103. The taxoid of claim 50, wherein-R represents ethoxyacetyl,
R.sub.2 represents a t-butyl radical, and Ar represents phenyl.
104. The taxoid of claim 50, wherein R represents isopropoxyacetyl,
R.sub.2 represents a t-butyl radical, and Ar represents phenyl.
105. A compound of the formula (XXII) 59in which G.sub.1 is an
alkoxyacetyl radical or other hydroxy-protecting group.
106. A method of preparing a compound of the formula (VI): 60in
which G.sub.1 is an alkoxyacetyl radical or other
hydroxy-protecting group, comprising reacting a compound of the
formula (XXII) 61with an alkali metal halide or an alkali metal
azide or a quaternary ammonium salt or an alkali metal phosphate in
an organic solvent and isolating the compound of formula (VI).
107. The method according to claim 106, wherein the compound of
formula XXII is prepared by reacting a compound of the formula XX:
62with trifluoro-methanesulfonic acid or a derivative thereof.
108. The method of claim 107, wherein the trifluoromethanesulphonic
acid derivative is trifluoromethanesulfonic acid anhydride or
N-phenyltrifluoromethanesulfonimide.
109. A compound of the formula XXIII: 63in which Ar represents an
aryl radical, R.sub.1 represents a benzoyl radical or a radical
R.sub.2--O--CO-- in which R.sub.2 represents: a straight or
branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl
radical containing 2 to 8 carbon atoms, an alkynyl radical
containing 3 to 8 carbon atoms, a cycloalkyl radical containing 3
to 6 carbon atoms, a cycloalkenyl radical containing 4 to 6 carbon
atoms or a bicycloalkyl radical containing 7 to 11 carbon atoms,
these radicals being optionally substituted by one or more
substituents chosen from halogen atoms and hydroxy radicals,
alkyloxy radicals containing 1 to 4 carbon atoms, dialkylamino
radicals in which each alkyl portion contains 1 to 4 carbon atoms,
piperidino radicals, morpholino radicals, 1-piperazinyl radicals
(optionally substituted at position 4 by alkyl radical containing 1
to 4 carbon atoms or by a phenylalkyl radical whose alkyl portion
contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to
6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon
atoms, phenyl radicals, cyano radicals, carboxy radicals or
alkyloxycarbonyl radicals whose alkyl portion contains 1 to 4
carbon atoms, or a phenyl radical optionally substituted by one or
more atoms or radicals chosen from halogen atoms and alkyl radicals
containing 1 to 4 carbon atoms or alkyloxy radicals containing 1 to
4 carbon atoms, or a saturated or unsaturated 4- to 6-membered
nitrogen-containing heterocyclyl radical optionally substituted by
one or more alkyl radicals containing 1 to 4 carbon atoms, it being
understood that the cycloalkyl, cycloalkenyl or bicycloalkyl
radicals may be optionally substituted by one or more alkyl
radicals containing 1 to 4 carbon atoms; R.sub.3 and R.sub.4, which
are identical or different represent a hydrogen atom or an alkyl
radical containing 1 to 4 carbon atoms, or an aralkyl radical whose
alkyl portion contains 1 to 4 carbon atoms and their aryl portion
preferably represents a phenyl radical optionally substituted by
one or more alkoxy radicals containing 1 to 4 carbon atoms, or an
aryl radical preferably representing a phenyl radical optionally
substituted by one or more alkoxy radicals containing 1 to 4 carbon
atoms, or alternatively R.sub.3 represents an alkoxy radical
containing 1 to 4 carbon atoms or a trihalomethyl radical such as
trichloromethyl or a phenyl radical substituted by a trihalomethyl
radical such as trichloromethyl and R.sub.4 represents a hydrogen
atom, or alternatively R.sub.3 and R.sub.4 form, together with the
carbon atom to which they are attached, a 4- to 7-membered ring,
and G.sub.1 represents an alkoxyacetyl radical or a
hydroxy-protecting group.
110. A compound according to claim 109, wherein Ar represents a
phenyl or .alpha.- or .beta.-naphthyl radical optionally
substituted by one or more atoms or radicals chosen from halogen
atoms and alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy,
alkylthio, aryloxy, arylthio, hydroxy, hydroxyalkyl, mercapto,
formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino,
alkylamino, dialkylamino, carboxy, alkoxycarbonyl, carbamoyl,
dialkylcabamoyl, cyano, nitro and trifluoromethyl radicals, with
the proviso that the alkyl radicals and the alkyl portions of the
other radicals contain 1 to 4 carbon atoms, that the alkenyl and
alkynyl radicals contain 2 to 8 carbon atoms and that the aryl
radicals are phenyl or .alpha.- or .beta.-naphthyl radicals or
alternatively Ar represents a 5-membered aromatic heterocyclic
radical containing one or more atoms, which are identical or
different, chosen from nitrogen, oxygen or sulphur atoms,
optionally substituted by one or more substituents, which are
identical or different, chosen from halogen atoms, and alkyl
radicals containing 1 to 4 carbon atoms, aryl radicals containing 6
to 10 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms,
aryloxy radicals containing 6 to 10 carbon atoms, amino radicals,
alkylamino radicals containing 1 to 4 carbon atoms, dialkylamino
radicals in which each alkyl portion contains 1 to 4 carbon atoms,
acylamino radicals in which the acyl portion contains 1 to 4 carbon
atoms, alkoxycarbonylamino radicals containing 1 to 4 carbon atoms,
acyl radicals containing 1 to 4 carbon atoms, arylcarbonyl radicals
in which the aryl portion contains 6 to 10 carbon atoms, cyano
radicals, carboxy radicals, carbamoyl radicals, alkylcarbamoyl
radicals in which the alkyl portion contains 1 to 4 carbon atoms,
dialkylcarbamoyl radicals in which each alkyl portion contains 1 to
4 carbon atoms or alkoxycarbonyl radicals in which the alkoxy
portion contains 1 to 4 carbon atoms.
111. A compound according to claim 109, wherein Ar represents a
phenyl, 2- or 3-thienyl or 2- or 3-furyl radical optionally
substituted by one or more atoms or radicals, which are identical
or different, chosen from halogen atoms and alkyl, alkoxy, amino,
alkylamino, dialkylamino, acylamino, alkoxycarbonylamino and
trifluoromethyl radicals.
112. A compound according to claim 109, wherein Ar represents a
phenyl radical optionally substituted by a chlorine or fluorine
atom or by an alkyl, alkoxy, dialkylamino, acylamino or
alkoxycarbonylamino or 2- or 3-thienyl or 2- or 3-furyl
radical.
113. A compound according to claim 109, wherein Ar represents a
phenyl radical and R.sub.1 represents a benzoyl or
tert-butoxcarbonyl radical.
114. A method of preparing a compound of the formula II: 64in which
Ar represents an aryl radical, R.sub.1 represents a benzoyl radical
or a radical R.sub.2--O--CO-- in which R.sub.2 represents: a
straight or branched alkyl radical containing 1 to 8 carbon atoms,
an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl
radical containing 3 to 8 carbon atoms, a cycloalkyl radical
containing 3 to 6 carbon atoms, a cycloalkenyl radical containing 4
to 6 carbon atoms or a bicycloalkyl radical containing 7 to 11
carbon atoms, these radicals being optionally substituted by one or
more substituents chosen from halogen atoms or hydroxy radicals,
alkyloxy radicals containing 1 to 4 carbon atoms, dialkylamino
radicals in which each alkyl portion contains 1 to 4 carbon atoms,
piperidino radicals, morpholino radicals, 1-piperazinyl radicals
(optionally substituted at position 4 by an alkyl radical
containing 1 to 4 carbon atoms or by a phenylalkyl radical whose
alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals
containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4
to 6 carbon atoms, phenyl radicals, cyano radicals, carboxy
radicals or alkyloxycarbonyl radicals whose alkyl portion contains
1 to 4 carbon atoms, or a phenyl radical optionally substituted by
one or more atoms or radicals chosen from halogen atoms and alkyl
radicals containing 1 to 4 carbon atoms or alkyloxy radicals
containing 1 to 4 carbon atoms, or a saturated or unsaturated 4- to
6-membered nitrogen-containing heterocyclyl radical optionally
substituted by one or more alkyl radicals containing 1 to 4 carbon
atoms, it being understood that the cycloalkyl, cycloalkenyl or
bicycloalkyl radicals may be optionally substituted by one or more
alkyl radicals containing 1 to 4 carbon atoms; R.sub.3 and R.sub.4,
which are identical or different represent a hydrogen atom or an
alkyl radical containing 1 to 4 carbon atoms, or an aralkyl radical
whose alkyl portion contains 1 to 4 carbon atoms and the aryl
portion preferably represents a phenyl radical optionally
substituted by one or more alkoxy radicals containing 1 to 4 carbon
atoms, or an aryl radical preferably representing a phenyl radical
optionally substituted by one or more alkyl radicals containing 1
to 4 carbon atoms, or alternatively R.sub.3 represents an alkoxy
radical containing 1 to 4 carbon atoms or a trihalomethyl radical
such as trichloromethyl or a phenyl radical substituted by a
trihalomethyl radical such as trichloromethyl and R.sub.4
represents a hydrogen atom, or alternatively R.sub.3 and R.sub.4
form, together with the carbon atom to which they are attached, a
4- to 7-membered ring, and G.sub.1 represents an alkoxyacetyl
radical or other hydroxy-protecting group, comprising reacting a
compound of the formula (XXIII): 65 with an alkali metal halide or
an alkali metal azide or a quaternary ammonium salt or an alkali
metal phosphate in an organic solvent and isolating the compound of
formula (II).
115. The method according to claim 114, wherein the compound of
formula XXIII is prepared by reacting a compound of the formula
XXIV: 66with trifluoro-methanesulfonic acid or a derivative
thereof.
116. The method of claim 115, wherein the trifluoramethanesulfonic
acid derivation is trifluoromethane sulfonic acid anhydrides or
N-phenyltrifluoromethanesulfonimide.
117. A method for the preparation of a taxoid of the formula 67in
which R represents an alkoxyacetyl radical, R.sub.1 represents a
benzoyl radical or a radical R.sub.2--O--CO-- in which R.sub.2
represents an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
bicycloalkyl, phenyl or heterocyclyl radical, and Ar represents an
aryl radical, comprising reacting a compound of the formula XXII
68in which G.sub.1 is an alkoxyacetyl radical or other
hydroxy-protecting group, with an alkali metal halide or an alkali
metal azide or a quaternary ammonium salt or an alkali metal
phosphate in an organic solvent to form a compound of the formula
VI: 69esterifying the product of formula VI: 70with a free acid of
the formula VII: 71or a derivative of the free acid capable of
being converted into the free acid, in which R.sub.3 represents a
hydrogen atom or an alkoxy radical containing 1 to 4 carbon atoms
or an optionally substituted aryl radical and R.sub.4 represents a
hydrogen atom, to give a product of the formula II: 72treating this
product in acidic medium to give a product of the formula III:
73and then optionally replacing the protecting group G.sub.1 by a
hydrogen atom or alkoxyacetyl radicals and alkoxyacetyl radical
being obtained by action of an alkoxyacetic acid or derivative
thereof on a compound obtained after replacement of G.sub.1 by a
hydrogen atom, and isolating the product (I) obtained.
118. A process according to claim 117, wherein the esterification
is carried out by means of the free acid, the procedure being
carried out in the presence of a condensing agent chosen from
carbodiimides and reactive carbonates and an activating agent
chosen from aminopyridines in an organic solvent chosen from
ethers, ketones, esters, nitriles, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from -10 to 90.degree. C.
119. A process according to claim 117, wherein the esterification
by means of an anhydride derivative of the free acid is carried out
in the presence of an activating agent chosen from aminopyridines
in an organic solvent chosen from ethers, esters, ketones,
nitrites, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons and aromatic hydrocarbons at a temperature ranging
from 0 to 90.degree. C.
120. A process according to claim 117, wherein the esterification
is carried out by means of a halide or anhydride derivative of the
free acid with an aliphatic or aromatic acid, optionally prepared
in situ, the procedure being carried out in the presence of a base
chosen from tertiary aliphatic amines in an organic solvent chosen
from ethers, esters, ketones, nitriles, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from 0 to 80.degree. C.
121. A process according to claim 117, wherein the acid treatment
is carried out by means of an inorganic or organic acid in an
organic solvent at a temperature ranging from -10 to 60.degree.
C.
122. A process according to claim 121, wherein the acid is chosen
from hydrochloric, sulphuric, acetic, methanesulphonic,
trifluoromethanesulphonic and p-toluenesulphonic acids, used alone
or in the form of a mixture.
123. A process according to claim 121, wherein the solvent is
chosen form alcohols, ethers, esters, halogenated aliphatic
hydrocarbons, aromatic hydrocarbons and nitriles.
124. A process according to claim 117, wherein the replacement by a
hydrogen atom of the protecting group G.sub.1, when it represents a
2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radical, is carried out by
treatment using zinc, optionally combined with copper, in the
presence of acetic acid at a temperature ranging from 30 to
60.degree. C. or by means of an inorganic or organic acid such as
hydrochloric acid or acetic acid in solution in an aliphatic
alcohol containing 1 to 3 carbon atoms or an aliphatic ester such
as ethyl acetate, isopropyl acetate or n-butyl acetate in the
presence of zinc optionally combined with copper, and, when it
represents an alkoxyacetyl radical, by treatment in alkaline medium
by means of ammonia in aqueous-alcoholic medium at a temperature
close to 20.degree. C. or by treatment using a zinc halide in
methanol at a temperature close to 20.degree. C.
125. A method for the preparation of a product of the formula I:
74in which R represents an alkoxyacetyl radical, R.sub.1 represents
a benzoyl radical or a radical R.sub.2--O--CO-- in which R.sub.2
represents an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
bicycloalkyl, phenyl or heterocyclyl radical, and Ar represents an
aryl radical, comprising reacting a compound of the formula XXII:
75with an alkali metal halide or an alkali metal azide or a
quaternary ammonium salt or an alkali metal phosphate in an organic
solvent to form a compound of the formula VI: 76esterifying a
product of the formula VI: 77in which G.sub.1 represents an
alkoxyacetyl radical or other hydroxy-protecting group, by means of
free acid of the formula VII: 78or a derivative of the free acid
capable of being converted into the free acid, in which R.sub.3 and
R.sub.4, which are identical or different, represent an alkyl
radical containing 1 to 4 carbon atoms or an aralkyl radical whose
alkyl portion contains 1 to 4 carbon atoms or an aryl radical, or
alternatively R.sub.3 represents a trihalomethyl radical or a
phenyl radical substituted by a trihalomethyl radical and R.sub.4
represents a hydrogen atom, or alternatively R.sub.3 and R.sub.4
form, together with the carbon atom to which they are attached, a
4- to 7-membered ring, to give, after treating in acidic medium, a
product of the formula IV: 79and acylating the product by means of
benzoyl chloride or a reactive derivative of the
formula:R.sub.2--O--CO--Xin which X represents a halogen atom or a
residue --O--R.sub.2 or --O--CO--O--R.sub.2, and then replacing the
protecting group G.sub.1, if necessary, by a hydrogen atom or an
alkoxyacetyl radical, alkoxyacetyl radical being obtained by action
of an alkoxyacetic acid or derivative thereof on a compound
obtained after replacement of G.sub.1 by a hydrogen atom, and
isolating the product obtained.
126. A process according to claim 125, wherein the esterification
is carried out by means of the free acid, the procedure being
carried out in the presence of a condensing agent chosen from
carbodiimides and reactive carbonates and an activating agent
chosen from aminopyridines in an organic solvent chosen from
ethers, ketones, esters, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from -10 to 90.degree. C.
127. A process according to claim 125, wherein the esterification
by means of an anhydride derivative of the free acid is carried out
in the presence of an activating agent chosen from aminopyridines
in an organic solvent chosen from ethers, esters, ketones,
nitrites, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons and aromatic hydrocarbons at a temperature ranging
from 0 to 90.degree. C.
128. A process according to claim 125, wherein the esterification
is carried out by means of a halide or anhydride derivative of the
free acid with an aliphatic or aromatic acid, optionally prepared
in situ, the procedure being carried out in the presence of a base
chosen from tertiary aliphatic amines in an organic solvent chosen
from ethers, esters, ketones, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from 0 to 80.degree. C.
129. A process according to claim 125, wherein the acid treatment
is carried out by means of an inorganic or organic acid in an
organic solvent at a temperature ranging from 0 to 50.degree.
C.
130. A process according to claim 129, wherein the acid is chosen
from hydrochloric, sulphuric and formic acids.
131. A process according to claim 129, wherein the solvent is
chosen from alcohols containing 1 to 3 carbon atoms.
132. A process according to claim 129, wherein the acylation is
carried out in an inert organic solvent in the presence of an
inorganic or organic base.
133. A process according to claim 126, wherein the inert organic
solvent is chosen from esters and halogenated aliphatic
hydrocarbons.
134. A process according to claim 128 wherein the procedure is
carried out at a temperature ranging from 0 to 50.degree. C.
135. A process according to claim 125, wherein the replacement by a
hydrogen atom of the protecting group G.sub.1, when it represents a
2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radical, is carried out by
treatment using zinc, optionally combined with copper, in the
presence of acetic acid at a temperature ranging from 30 to
60.degree. C. or by means of an inorganic or organic acid such as
hydrochloric acid or acetic acid in solution in an aliphatic
alcohol containing 1 to 3 carbon atoms or an aliphatic ester such
as ethyl acetate, isopropyl acetate or n-butyl acetate in the
presence of zinc optionally combined with copper, or, when it
represents an alkoxy acetyl radical, by treatment in alkaline
medium by means of ammonia in aqueous-alcoholic medium at a
temperature close to 20.degree. C. or by treatment using a zinc
halide in ethanol at a temperature close to 20.degree. C.
136. A method for the preparation of a taxoid of the formula I:
80in which R represents an alkoxyacetyl radical, R.sub.1 represents
a benzoyl radical or a radical R.sub.2--O--CO-- in which R.sub.2
represents an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
bicycloalkyl, phenyl or heterocyclyl radical, and Ar represents an
aryl radical, comprising reacting a compound of the formula XXII:
81in which G.sub.1 represents a hydroxy-protecting group, with an
alkali metal halide or an alkali metal azide or a quaternary
ammonium salt or an alkali metal phosphate in an organic solvent to
form a compound of the formula VI: 82esterifying a product of the
formula VI: 83by means of a free acid of the formula XXVI: 84or a
derivative of the free acid capable of being converted into the
free acid, in which G.sub.3 represents a hydroxy-protecting group,
or of an activated derivative of this acid, to give a product of
the formula XXVII: 85replacing the protecting groups G.sub.3 and
optionally G.sub.1 by a hydrogen atom or an alkoxyacetyl radical,
said alkoxyacetyl radical being obtained by action of an
alkoxyacetic acid or derivative thereof on a compound obtained
after replacement of G.sub.1 by a hydrogen atom, and isolating the
product (I) obtained.
137. A process according to claim 136, wherein the esterification
is carried out by means of the free acid, the procedure being
carried out in the presence of a condensing agent chosen from
carbodiimides and reactive carbonates and an activating agent
chosen from aminopyridines in an organic solvent chosen from
ethers, ketones, esters, nitrites aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature of between -10 to 90.degree. C.
138. A process according to claim 136, wherein the esterification
by means of an anhydride derivative of the free acid is carried out
in the presence of an activating agent chosen from aminopyridines
in an organic solvent chosen from ethers, esters, ketones,
nitrites, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons and aromatic hydrocarbons at a temperature ranging
from 0 to 90.degree. C.
139. A process according to claim 136, wherein the esterification
is carried out by means of a halide or anhydride derivative of the
free acid with an aliphatic or aromatic acid, optionally prepared
in situ, the procedure being carried out in the presence of a base
chosen from tertiary aliphatic amines in an organic solvent chosen
from ethers, esters, ketones, nitrites, aliphatic hydrocarbons,
halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a
temperature ranging from 0 to 80.degree. C.
140. A process according to claim 136, wherein the replacement of
the protecting groups G.sub.1 and G.sub.3 by hydrogen atoms is
carried out by treatment with zinc, optionally combined with
copper, in the presence of acetic acid at a temperature ranging
from 30 to 60.degree. C. or by means of an inorganic or organic
acid such as hydrochloric acid or acetic acid in solution in an
aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic
ester such as ethyl acetate, isopropyl acetate or n-butyl acetate
in the presence of zinc optionally combined with copper, when
G.sub.1 and G.sub.3 represent a 2,2,2-trichloroethoxycarbonyl or
2-(2-trichloro-methylpropoxy)carbonyl radical, or by treatment in
acidic medium such as for example hydrochloric acid in solution in
an aliphatic alcohol containing 1 to 3 carbon atoms (methanol,
ethanol, propanol or isopropanol) or aqueous hydrofluoric acid at a
temperature ranging from 0 to 40.degree. C. when G.sub.3 represents
a silylated radical or an acetal residue, followed by the
replacement of the protecting group G.sub.1 by treatment using
zinc, optionally combined with copper, in the presence of acetic
acid at a temperature ranging from 30 to 60.degree. C. or by means
of an inorganic or organic acid such as hydrochloric acid or acetic
acid in solution in an aliphatic alcohol containing 1 to 3 carbon
atoms or an aliphatic ester such as ethyl acetate, isopropyl
acetate or n-butyl acetate in the presence of zinc optionally
combined with copper, or, when G.sub.1 represents an alkoxyacetyl
radical, by treatment in alkaline medium by means of ammonia in
aqueous-alcoholic medium at a temperature close to 20.degree. C. or
by treatment using a zinc halide in methanol at a temperature close
to 20.degree. C.
141. A process according to claim 136, wherein when G.sub.3
represents a radical --CH.sub.2--Ph, the replacement of the group
by a hydrogen atom is carried out by hydrogenolysis after replacing
the protecting group G.sub.1.
142. A method for the preparation of a taxoid of the formula (I):
86in which R represents an alkoxyacetyl radical, R.sub.1 represents
a benzoyl radical or a radical R.sub.2--O--CO in which R.sub.2
represents an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
bicycloalkyl, phenyl or heterocyclyl radical, and Ar represents an
aryl radical, comprising esterifying a compound of the formula
(XXIX): 87in which G.sub.1 represents an alkoxyacetyl radical or
other hydroxy-protecting group and Ra represents a radical
O--SO.sub.2--CF.sub.3 or forms, together with the carbon atom of
the a methyl group, a cyclopropyl ring, with a lactam of the
formula (XXX): 88wherein G.sub.3 is a hydroxy-protecting group
chosen from methoxymethyl, 1-ethoxyethyl, benzyloxymethyl,
(.beta.-trimethylsilyloxy)methyl, tetrahydropyranyl,
2,2,2-trichloroethoxymethyl, 2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radicals, or CH.sub.2--Ph
radicals in which Ph represents a phenyl radical optionally
substituted by one or more atoms or radicals, which are identical
or different, chosen from halogen atoms and alkyl radicals
containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4
carbon atoms, and Ar and R.sub.1 are defined as above, optionally
transforming the O--SO.sub.2--CF.sub.3 radical into a cyclopropyl
ring; and replacing G.sub.3 by a hydrogen atom and optionally
G.sub.1 by a hydrogen atom, said method comprising the further
step, if G.sub.1 is replaced by a hydrogen atom, of converting said
G.sub.1 hydrogen atom to an alkoxyacetyl radical by action of an
alkoxyacetic acid or derivative thereof on a compound obtained
after replacement of G.sub.1 by said hydrogen atom.
143. A method for the preparation of a taxoid of the formula (I):
89wherein R represents butoxyacetyl, ethoxyacetyl, and
isopropoxyacetyl, R.sub.1 represents a t-butoxycarbonyl radical,
and Ar represents phenyl; comprising esterfying with an
alkoxyacetic acid or derivative thereof, a compound of the formula
(II): 90wherein G.sub.1 represents a hydrogen atom, and R.sub.3 and
R.sub.4, which are identical or different, represent a hydrogen
atom or an alkyl radical containing 1 to 4 carbon atoms, or an
aralkyl radical whose alkyl portion contains 1 to 4 carbon atoms
and the aryl portion preferably represents a phenyl radical
optionally substituted by one or more alkoxy radicals containing 1
to 4 carbon atoms, or an aryl radical preferably representing a
phenyl radical optionally substituted by one or more alkoxy
radicals containing 1 to 4 carbon atoms, or alternatively R.sub.3
represents an alkoxy radical containing 1 to 4 carbon atoms or a
trihalomethyl radical such as trichloromethyl or a phenyl radical
substituted by a trihalomethyl radical such as trichloromethyl and
R.sub.4 represents a hydrogen atom, or alternatively R.sub.3 and
R.sub.4 form, together with the carbon atom to which they are
attached, a 4- to 7-membered ring, and opening the oxazaldine ring
portoin of the compound of formula (II) to obtain the compound of
formula (I).
144. The method of claim 143, wherein the alkoxyacetic acid is
selected from butoxyacetic acid, ethoxyacetic acid, and
isoproxyacetic acid.
145. A method for the preparation of a taxoid of the formula (I):
91in which R represents an alkoxyacetyl radical, R.sub.1 represents
a benzoyl radical or a radical R.sub.2--O--CO in which R.sub.2
represents an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
bicycloalkyl, phenyl or heterocyclyl radical, and Ar represents an
aryl radical, comprising esterifying a compound of the formula
(XXIX): 92in which G.sub.1 represents an alkoxyacetyl radical or
other hydroxy-protecting group and Ra represents a radical
O--SO.sub.2--CF.sub.3 or forms, together with the carbon atom of
the a methyl group, a cyclopropyl ring, with a free acid of the
formula (VII): 93in which R.sub.3 and R.sub.4, which are identical
or different represent a hydrogen atom or an alkyl radical
containing 1 to 4 carbon atoms, or an aralkyl radical whose alkyl
portion contains 1 to 4 carbon atoms and the aryl portion
preferably represents a phenyl radical optionally substituted by
one or more alkoxy radicals containing 1 to 4 carbon atoms, or an
aryl radical preferably representing a phenyl radical optionally
substituted by one or more alkoxy radicals containing 1 to 4 carbon
atoms, or alternatively R.sub.3 represents an alkoxy radical
containing 1 to 4 carbon atoms or a trihalomethyl radical such as
trichloromethyl or a phenyl radical substituted by a trihalomethyl
radical such as trichloromethyl and R.sub.4 represents a hydrogen
atom, or alternatively R.sub.3 and R.sub.4 form, together with the
carbon atom to which they are attached, a 4- to 7-membered ring;
and Ar and R.sub.1 are defined as above; optionally transforming
the O--SO.sub.2--CF.sub.3 radical into a cyclopropyl ring; and
removing, if G.sub.1 is said other hydroxy-protecting group, said
hydroxy-protecting group to obtain a hydrogen atom and converting
said hydrogen atom to an alkoxyacetyl radical by action of an
alkoxyacetic acid or derivative thereof on said compound obtained
after replacement of said G.sub.1 hydroxy-protecting group by a
hydrogen atom.
Description
[0001] This application is a continuation-in-part of Ser. No.
08/162,984, field Dec. 8, 1993, the disclosure of which is
specifically incorporated by reference herein.
[0002] The present invention relates to new taxoids of general
formula: 2
[0003] their preparation and pharmaceutical compositions containing
them.
[0004] In general formula (I),
[0005] Ar represents an aryl radical,
[0006] R represents a hydrogen atom or an acetyl, alkoxyacetyl or
alkyl radical,
[0007] R.sub.1 represents a benzoyl radical or a radical
R.sub.2--O--CO-- in which R.sub.2 represents:
[0008] a straight or branched alkyl radical containing 1 to 8
carbon atoms; an alkenyl radical containing 2 to 8 carbon atoms; an
alkynyl radical containing 3 to 8 carbon atoms; a cycloalkyl
radical containing 3 to 6 carbon atoms; a cycloalkenyl radical
containing 4 to 6 carbon atoms or a bicycloalkyl radical containing
7 to 11 carbon atoms; these radicals being optionally substituted
by one or more substituents chosen from halogen atoms and hydroxy
radicals; alkyloxy radicals containing 1 to 4 carbon atoms;
dialkylamino radicals in which each alkyl portion contains 1 to 4
carbon atoms; piperidino radicals; morpholino radical;
1-piperazinyl radicals (optionally substituted at position 4 by an
alkyl radical containing 1 to 4 carbon atoms or by a phenylalkyl
radical whose alkyl portion contains 1 to 4 carbon atoms);
cycloalkyl radicals containing 3 to 6 carbon atoms; cycloalkenyl
radicals containing 4 to 6 carbon atoms; phenyl radicals; cyano
radicals; carboxy radicals or alkyloxycarbonyl radicals whose alkyl
portion contains 1 to 4 carbon atoms,
[0009] or a phenyl radical optionally substituted by one or more
atoms or radicals chosen from halogen atoms and alkyl radicals
containing 1 to 4 carbon atoms or alkyloxy radicals containing 1 to
4 carbon atoms,
[0010] or a saturated or unsaturated 4- to 6-membered
nitrogen-containing heterocyclyl radical optionally substituted by
one or more alkyl radicals containing 1 to 4 carbon atoms, it being
understood that the cycloalkyl, cycloalkenyl or bicycloalkyl
radicals may be optionally substituted by one or more alkyl
radicals containing 1 to 4 carbon atoms.
[0011] Preferably, Ar represents a phenyl or .alpha.- or
.beta.-naphthyl radical optionally substituted by one or more atoms
or radicals chosen from halogen atoms (fluorine, chlorine, bromine,
or iodine) and alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy,
alkylthio, aryloxy, arylthio, hydroxy, hydroxyalkyl, mercapto,
formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino,
alkylamino, dialkylamino, carboxy, alkoxycarbonyl, carbamoyl,
dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals;
[0012] it being understood that the alkyl radicals and the alkyl
portions of the other radicals contain 1 to 4 carbon atoms;
[0013] that the alkenyl and alkynyl radicals contain 2 to 8 carbon
atoms; and
[0014] that the aryl radicals are phenyl or .alpha.- or
.beta.-naphthyl radicals or alternatively Ar represents a
5-membered aromatic heterocyclic radical containing one or more
hetero atoms, which are identical or different, chosen from
nitrogen, oxygen or sulphur atoms;
[0015] Ar optionally being substituted by one or more substituents,
which are identical or different, chosen from halogen atoms
(fluorine, chlorine, bromine or iodine) and alkyl radicals
containing 1 to 4 carbon atoms, aryl radicals containing 6 to 10
carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms,
aryloxy radicals containing 6 to 10 carbon atoms, amino radicals,
alkylamino radicals containing 1 to 4 carbon atoms, dialkylamino
radicals in which each alkyl portion contains 1 to 4 carbon atoms,
acylamino radicals in which the acyl portion contains 1 to 4 carbon
atoms, alkoxycarbonylamino radicals containing 1 to 4 carbon atoms,
acyl radicals containing 1 to 4 carbon atoms, arylcarbonyl radicals
in which the aryl portion contains 6 to 10 carbon atoms, cyano
radicals, carboxy radicals, carbamoyl radicals, alkylcarbamoyl
radicals in which the alkyl portion contains 1 to 4 carbon atoms,
dialkylcarbamoyl radicals in which each alkyl portion contains 1 to
4 carbon atoms or alkoxycarbonyl radicals in which the alkoxy
portion contains 1 to 4 carbon atoms.
[0016] More particularly, Ar represents a phenyl, 2- or 3-thienyl
or 2- or 3-furyl radical optionally substituted by one or more
atoms or radicals, which are identical or different, chosen from
halogen atoms, and alkyl, alkoxy, amino, alkylamino, dialkylamino,
acylamino, alkoxycarbonylamino and trifluoromethyl radicals.
[0017] Still more particularly, Ar represents a phenyl radical
optionally substituted by a chlorine or fluorine atom or by an
alkyl (methyl), alkoxy (methoxy), dialkylamino (diethylamino),
acylamino (acetylamino) or alkoxycarbonylamino
(tert-butoxycarbonylamino) or 2- or 3-thienyl or 2- or 3-furyl
radical.
[0018] Regarding the alkoxyacetyl radical for R, the alkoxy portion
thereof preferably contains 1 to 8 carbon atoms and, more
preferably, 1 to 4 carbon atoms. The alkoxy portion may be linear
or branched. Preferred alkoxyacetyl groups include saturated groups
such as methoxyacetyl (CH.sub.3OCH.sub.2C(O)--), ethoxyacetyl
(CH.sub.3CH.sub.2OCH.sub.2C(O)--), isopropoxyacetyl
((CH.sub.3).sub.2CHOCH.sub.2C(O)--), and butoxyacetyl
(CH.sub.3CH.sub.2CH.sub.2CH.sub.2OCH.sub.2C(O)--).
[0019] Of even more special interest are the products of general
formula (I) in which Ar represents a phenyl or 3-thienyl radical
and R.sub.1 represents a benzoyl or tert-butoxycarbonyl
radical.
[0020] According to the present invention, the new taxoids of
general formula (I) can be obtained from a product of general
formula: 3
[0021] in which Ar and R.sub.1 are defined as above, and
[0022] R.sub.3 and R.sub.4, which are identical or different
represent a hydrogen atom or an alkyl radical containing 1 to 4
carbon atoms, or an aralkyl radical whose alkyl portion contains 1
to 4 carbon atoms and the aryl portion preferably represents a
phenyl radical optionally substituted by one or more alkoxy
radicals containing 1 to 4 carbon atoms, or an aryl radical
preferably representing a phenyl radical optionally substituted by
one or more alkoxy radicals containing 1 to 4 carbon atoms, or
[0023] alternatively R.sub.3 represents an alkoxy radical
containing 1 to 4 carbon atoms or a trihalomethyl radical such as
trichloromethyl or a phenyl radical substituted by a trihalomethyl
radical such as trichloromethyl and R.sub.4 represents a hydrogen
atom, or
[0024] alternatively R.sub.3 and R.sub.4 form, together with the
carbon atom to which they are attached, a 4- to 7-membered ring,
and G.sub.1 represents a hydrogen atom or an acetyl, alkoxyacetyl
or alkyl radical or a hydroxy-protecting group, the procedure being
carried out, according to the meanings of R.sub.3 and R.sub.4, in
the following manner:
[0025] 1) when R.sub.3 represents a hydrogen atom or an alkoxy
radical containing 1 to 4 carbon atoms or an optionally substituted
aryl radical and R.sub.4 represents a hydrogen atom, the product of
general formula (II) is treated in acidic medium in order to obtain
a product of general formula: 4
[0026] in which Ar, R.sub.1 and G.sub.1 are defined as above, whose
G.sub.1 radical is, if necessary, replaced by a hydrogen atom or an
alkoxyacetyl radical, said alkoxyacetyl radical being obtained by
action of an alkoxyacetic acid or derivative thereof on a compound
of formula (III) wherein G.sub.1 represents a hydrogen atom.
[0027] Regarding the alkoxyacetyl radical for G.sub.1, the alkoxy
portion thereof preferably contains 1 to 8 carbon atoms and, more
preferably, 1 to 4 carbon atoms. The alkoxy portion may be linear
or branched. Preferred alkoxyacetyl groups include saturated groups
such as methoxyacetyl (CH.sub.3CH.sub.2C(O)--), ethoxyacetyl
(CH.sub.3CH.sub.2OCH.sub.2C(O)--), isopropoxyacetyl
((CH.sub.3).sub.2CHOCH.sub.2C(O)--), and butoxyacetyl
(CH.sub.3CH.sub.2CH.sub.2CH.sub.2OCH.sub.2C(O)--)
[0028] The deprotection of the side chain of the product of general
formula (II) can also be carried out in the presence of an
inorganic acid (hydrochloric acid or sulphuric acid) or an organic
acid (acetic acid, methanesulphonic acid, trifluoromethanesulphonic
acid or p-toluenesulphonic acid), used alone or in the form of a
mixture, the procedure being carried out in an organic solvent
chosen from alcohols (methanol, ethanol or isopropanol), ethers
(tetrahydrofuran, diisopropyl ether or methyl t-butyl ether),
esters (ethyl acetate, isopropyl acetate or n-butyl acetate),
aliphatic hydrocarbons (pentane, hexane or heptane), halogenated
aliphatic hydrocarbons (dichloromethane or 1,2-dichloroethane),
aromatic hydrocarbons (benzene, toluene or xylenes) and nitriles
(acetonitrile) at a temperature ranging from -10 to 60.degree. C.,
preferably from 15 to 30.degree. C. The acid may be used in a
catalytic or stoichiometric quantity or in excess.
[0029] The deprotection can also be carried out under oxidizing
conditions, using for example ammonium cerium(IV) nitrate in an
acetonitrile-water mixture or
2,3-dichloro-5,6-dicyano-1,4-benzoquinone in water.
[0030] The deprotection can also be carried out under reducing
conditions, for example by hydrogenolysis in the presence of a
catalyst.
[0031] When G.sub.1 represents a protecting group, it is preferably
a 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)
carbonyl radical whose replacement by a hydrogen atom is carried
out using zinc, optionally combined with copper, in the presence of
acetic acid, at a temperature ranging from 20 to 60.degree. C. or
by means of an inorganic or organic acid such as hydrochloric acid
or acetic acid in a solution in an aliphatic alcohol containing 1
to 3 carbon atoms or in an aliphatic ester such as ethyl acetate,
isopropyl acetate or n-butyl acetate in the presence of zinc
optionally combined with copper, or alternatively, when G.sub.1
represents an alkoxyacetyl radical, its optional replacement by a
hydrogen atom is carried out by treatment in alkaline medium or by
the action of a zinc halide under conditions which do not affect
the rest of the molecule. Generally, the alkaline treatment is
carried out by the action of ammonia in aqueous-alcoholic medium,
at a temperature close to 20.degree. C. Generally, the treatment
with a zinc halide, preferably zinc iodide, is carried out in
methanol at a temperature close to 20.degree. C.
[0032] 2) when R.sub.3 and R.sub.4, which are identical or
different, represent an alkyl radical containing 1 to 4 carbon
atoms, or an aralkyl radical whose alkyl portion contains 1 to 4
carbon atoms and the aryl portion is preferably an optionally
substituted phenyl radical, or alternatively R.sub.3 represents a
trihalomethyl radical or a phenyl radical substituted by a
trihalomethyl radical and R.sub.4 represents a hydrogen atom, or
alternatively R.sub.3 and R.sub.4 form, together with the carbon
atom to which they are attached, a 4- to 7-membered ring, the
product of general formula (II) is converted to the product of
general formula: 5
[0033] in which Ar and G.sub.1 are defined as above, which is
acylated by means of benzoyl chloride or a reactive derivative of
general formula:
R.sub.2--O--CO--X (V)
[0034] in which R.sub.2 is defined as above and X represents a
halogen atom (fluorine or chlorine) or a residue --O--R.sub.2 or
--O--CO--O--R.sub.2, to give a product of general formula (III) in
which Ar, R.sub.1 and G.sub.1 are defined as above, whose G.sub.1
radical is, if necessary, replaced by a hydrogen atom and then by
an alkoxyacetyl radical, said alkoxyacetyl radical being obtained
by action of an alkoxyacetic acid or a derivative therof on a
compound represented by the formula (I) wherein R represents a
hydrogen atom.
[0035] The products of general formula (IV) can be obtained by
treating a product of general formula (II), in which Ar, R.sub.1
and G.sub.1 are defined as above, R.sub.3 and R.sub.4, which are
identical or different, represent an alkyl, aralkyl or aryl
radical, or alternatively R.sub.3 and R.sub.4 form together with
the carbon atom to which they are attached a 4- to 7-membered ring,
with an inorganic acid (preferably hydrochloric acid or sulphuric
acid) or an organic acid (preferably formic acid) optionally in an
alcohol containing 1 to 3 carbon atoms (preferably methanol,
ethanol or isopropanol) at a temperature ranging from 0 to
50.degree. C. Preferably, formic acid is used at a temperature
close to 20.degree. C.
[0036] The acylation of the product of general formula (IV) by
means of benzoyl chloride or a reactive derivative of general
formula (V) is carried out in an inert organic solvent chosen from
esters such as ethyl acetate, isopropyl acetate or n-butyl acetate
and halogenated aliphatic hydrocarbons such as dichloromethane or
1,2-dichloroethane in the presence of an inorganic base such as
sodium bicarbonate or an organic base such as triethylamine. The
reaction is carried out at a temperature ranging from 0 to
50.degree. C., preferably close to 20.degree. C.
[0037] When the radical G.sub.1 represents a protecting group, its
replacement by a hydrogen atom is carried out under the conditions
described above.
[0038] The products of general formula (II) can be obtained
according to one of the following methods:
[0039] 1) by esterification of the product of general formula:
6
[0040] in which G.sub.1 is defined as above, by means of an acid of
general formula: 7
[0041] in which Ar, R.sub.1, R.sub.3 and R.sub.4 are defined as
above, or of a derivative of this acid.
[0042] The esterification by means of an acid of general formula
(VII) can be carried out in the presence of a condensing agent
(carbodiimide, reactive carbonate) and an activating agent
(aminopyridine) in an organic solvent (ether, ester, ketones,
nitrites, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons or aromatic hydrocarbons) at a temperature ranging
from -10 to 90.degree. C.
[0043] The esterification may also be performed using the acid of
general formula (VII) in anhydride form, the procedure being
carried out in the presence of an activating agent (aminopyridine)
in an organic solvent (ethers, esters, ketones, nitriles, aliphatic
hydrocarbons, halogenated aliphatic hydrocarbons or aromatic
hydrocarbons) at a temperature ranging from 0 to 90.degree. C.
[0044] The esterification can also be performed using the acid of
general formula (VII) in halide form or in anhydride form with an
aliphatic or aromatic acid, optionally prepared in situ, in the
presence of a base (tertiary aliphatic amine), the procedure being
carried out in an organic solvent (ethers, esters, ketones,
nitrites, aliphatic hydrocarbons, halogenated aliphatic
hydrocarbons or aromatic hydrocarbons) at a temperature ranging
from 0 to 80.degree. C.
[0045] The acid of general formula (VII) can be obtained by
saponification of an ester of general formula: 8
[0046] in which Ar, R.sub.1, R.sub.3 and R.sub.4 are defined as
above and R.sub.5 represents an alkyl radical containing 1 to 4
carbon atoms optionally substituted by a phenyl radical.
[0047] Generally, the saponification is carried out by means of an
inorganic base (alkali metal hydroxide, carbonate or bicarbonate)
in aqueous-alcoholic medium (methanol-water) at a temperature
ranging from 10 to 40.degree. C.
[0048] The ester of general formula (VIII) can be obtained by the
action of a product of general formula: 9
[0049] in which R.sub.3 and R.sub.4 are defined as above in the
form of a dialkylacetal or an enol alkyl ether, on an ester of
general formula: 10
[0050] in which Ar, R.sub.1 and R.sub.5 are defined as above, the
procedure being carried out in an inert organic solvent (aromatic
hydrocarbon) in the presence of a strong inorganic acid (sulphuric
acid) or organic acid (p-toluenesulphonic acid optionally in the
form of a pyridinium salt) at a temperature ranging from 0.degree.
C. to the boiling temperature of the reaction mixture.
[0051] The ester of general formula (X) can be obtained by the
action of a product of general formula (V) on an ester of general
formula: 11
[0052] in which Ar and R.sub.5 are defined as above, the procedure
being carried out in an organic solvent (ester, halogenated
aliphatic hydrocarbon) in the presence of an inorganic or organic
base at a temperature ranging from 0 to 50.degree. C.
[0053] The product of general formula (XI) can be obtained by
reduction of an azide of general formula: 12
[0054] in which Ar and R.sub.5 are defined above, by means of
hydrogen in the presence of a catalyst such as palladium on carbon,
the procedure being carried out in an organic solvent (ester).
[0055] The product of general formula (XII) can be obtained by the
action of an azide such as trimethylsilyl azide in the presence of
zinc chloride or alkali metal (sodium, potassium or lithium) azide
in aqueous-organic medium (water-tetrahydrofuran) at a temperature
ranging from 20.degree. C. to the boiling temperature of the
reaction mixture, on an epoxide of general formula: 13
[0056] in which Ar and R.sub.5 are defined as above, optionally
prepared in situ.
[0057] The epoxide of general formula (XIII) can be obtained,
optionally in situ, by dehydrohalogenation of a product of general
formula: 14
[0058] in which Ar is defined as above, Hal represents a halogen
atom, preferably a bromine atom, and R.sub.6 and R.sub.7, which are
identical or different, represent a hydrogen atom or an alkyl
radical containing 1 to 4 carbon atoms or a phenyl radical, at
least one being an alkyl radical or a phenyl radical, by means of a
alkali-metal alcoholate, optionally prepared in situ, in an inert
organic solvent such as tetrahydrofuran at a temperature ranging
from -80.degree. C. to 25.degree. C.
[0059] The product of general formula (XIV) can be obtained by the
action of an aldehyde of general formula:
Ar--CHO (XV)
[0060] in which Ar is defined as above, on a halide of general
formula: 15
[0061] in which Hal, R.sub.6 and R.sub.7 are defined as above,
anionized beforehand.
[0062] Generally, the procedure is carried out in an inert organic
solvent chosen from ethers (ethyl ether) and halogenated aliphatic
hydrocarbons (methylene chloride) at a temperature ranging from -80
to 25.degree. C., in the presence of a tertiary amine
(triethylamine) and an enolysing agent (di-n-butylboron
triflate).
[0063] The product of general formula (XVI) can be obtained by the
action of a halide of a haloacetic acid, preferably bromoacetic
acid bromide, on the corresponding oxazolidinone.
[0064] The product of general formula (XI) can be obtained by
hydrogenolysis of a product of general formula: 16
[0065] in which Ar and R.sub.5 are defined as above and Ph
represents an optionally substituted phenyl radical.
[0066] Generally, the hydrogenolysis is carried out by means of
hydrogen in the presence of a catalyst. More particularly,
palladium on carbon containing 1 to 10% by weight of palladium or
palladium dihydroxide containing 20% by weight of palladium is used
as catalyst.
[0067] The hydrogenolysis is carried out in an organic solvent or
in a mixture of organic solvents. It is advantageous to carry out
the procedure in acetic acid optionally combined with an aliphatic
alcohol containing 1 to 4 carbon atoms such as a mixture of acetic
acid-methanol at a temperature ranging from 20 to 80.degree. C.
[0068] The hydrogen necessary for the hydrogenolysis can also be
provided by a compound which liberates hydrogen by chemical
reaction or by thermal decomposition (ammonium formate). It is
advantageous to carry out the procedure at a hydrogen pressure
ranging from 1 to 50 bar.
[0069] The product of general formula (XVII) can be obtained by
hydrolysis or alcoholysis of a product of general formula: 17
[0070] in which Ar and Ph are defined as above.
[0071] It is particularly advantageous to carry out an alcoholysis
by means of an alcohol of formula R.sub.5--OH in which R.sub.5 is
defined as above, the procedure being carried out in acidic
medium.
[0072] Preferably, the alcoholysis is carried out by means of
methanol in the presence of a strong inorganic acid such as
hydrochloric acid at a temperature close to the reflux temperature
of the reaction mixture.
[0073] The product of general formula (XVIII) can be obtained by
saponification of an ester of general formula: 18
[0074] in which Ar and Ph are defined as above and R.sub.8
represents an alkyl, phenylalkyl or phenyl radical, followed by
separation of the 3R, 4S diastereoisomer of general formula (XVII)
from the other diastereoisomers.
[0075] Generally, the saponification is carried out by means of an
inorganic or organic base such as ammonium hydroxide, lithium
hydroxide, sodium hydroxide or potassium hydroxide in a suitable
solvent such as a methanol-water or tetrahydrofuran-water mixture
at a temperature ranging from 10-.degree. C. to 20.degree. C.
[0076] The separation of the 3R, 4S diastereoisomer can be carried
out by selective crystallization from a suitable organic solvent
such as ethyl acetate.
[0077] The product of general formula (XIX) can be obtained by
cycloaddition of an imine of general formula: 19
[0078] in which Ar and Ph are defined as above, onto an acid halide
of general formula: 20
[0079] in which R.sub.8 is defined as above and Y represents a
halogen atom such as a bromine or chlorine atom.
[0080] Generally, the reaction is carried out at a temperature
ranging from 0 to 50.degree. C. in the presence of a base chosen
from aliphatic tertiary amines (triethylamine) or pyridine in an
organic solvent chosen from optionally halogenated aliphatic
hydrocarbons (methylene chloride or chloroform) and aromatic
hydrocarbons (benzene, toluene or xylenes).
[0081] The product of general formula (XX) can be obtained under
conditions analogous to those described by M. Furukawa et al.,
Chem. Phar. Bull., 25 (1), 181-184 (1977).
[0082] The product of general formula (VI) can be obtained by the
action of an alkali metal halide (sodium iodide or potassium
fluoride) or an alkali metal azide (sodium azide) or a quaternary
ammonium salt or an alkali metal phosphate, on a baccatin III or
10-deacetylbaccatin III derivative of general formula: 21
[0083] in which G.sub.1 is defined as above.
[0084] Generally, the reaction is carried out in an organic solvent
chosen from ethers (tetrahydrofuran, diisopropyl ether, methyl
t-butyl ether) and nitriles (acetonitrile), alone or in the form of
a mixture, at a temperature ranging from 20.degree. C. to the
boiling temperature of the reaction mixture.
[0085] The product of formula (XXII) in which G.sub.1 represents a
hydrogen atom or an acetyl, alkoxyacetyl or alkyl radical can be
obtained by the action of a trifluoromethanesulphonic acid
derivative such as the anhydride or
N-phenyltrifluoromethanesulphonimide, on baccatin III or
10-deacetylbaccatin III, which can be extracted according to known
methods from yew leaves (Taxus baccata), optionally followed by
protection in position 10, it being understood that in order to
obtain a product of general formula (XXII) in which G.sub.1
represents an alkoxyacetyl or alkyl radical, it is necessary to
treat beforehand the 10-deacetylbaccatin III protected in position
7, preferably with a silylated radical, with an alkoxy acetic acid
halide or with an alkyl halide.
[0086] Generally, the reaction of a trifluoromethanesulphonic acid
derivative is carried out in an inert organic solvent (optionally
halogenated aliphatic hydrocarbons, or aromatic hydrocarbons) in
the presence of an organic base such as an aliphatic tertiary amine
(triethylamine) or pyridine, at a temperature ranging from -50 to
+20.degree. C.
[0087] Generally, the introduction of an alkoxyacetyl group is
carried out by treating the protected 10-deacetylbaccatin III with
an alkoxyacetic acid halide, the procedure being carried out in a
basic organic solvent such as pyridine at a temperature close to
20.degree. C.
[0088] Generally, the introduction of an alkyl radical is carried
out by treating the 10-deacetylbaccatin III, protected and
metallized in position 10, by means, for example, of a alkali metal
hydride (sodium hydride) or a metallic alkylide (butyllithium),
with an alkyl halide.
[0089] 2) by the action of an alkali metal halide (sodium iodide or
potassium fluoride) or an alkali metal azide (sodium azide) or a
quaternary ammonium salt or an alkali metal phosphate on a product
of general formula: 22
[0090] in which Ar, R.sub.1, R.sub.3, R.sub.4 and G.sub.1 are
defined as above.
[0091] Generally, the reaction is carried out in an organic solvent
chosen from ethers (tetrahydrofuran, diisopropyl ether or methyl
t-butyl ether) and nitrites (acetonitrile), alone or in the form of
a mixture, at a temperature ranging from 20.degree. C. to the
boiling temperature of the reaction mixture.
[0092] The product of general formula (XXIII) can be obtained by
the action of a trifluoromethanesulphonic acid derivative such as
the anhydride or N-phenyltrifluoromethanesulphonimide on a taxoid
of general formula: 23
[0093] in which Ar, R.sub.1, R.sub.3, R.sub.4 and G.sub.1 are
defined as above.
[0094] Generally, the reaction is carried out in an inert organic
solvent (optionally halogenated aliphatic hydrocarbons, or aromatic
hydrocarbons) in the presence of an organic base such as an
aliphatic tertiary amine (triethylamine) or pyridine, at a
temperature ranging from -50 to +20.degree. C.
[0095] The taxoid of general formula (XXIV), in which G.sub.1
represents a hydrogen atom or an alkoxyacetyl radical, can be
obtained from a product of general formula: 24
[0096] in which Ar, R.sub.1, R.sub.3, R.sub.4 are defined as above,
G'.sub.1 represents a hydroxy-protecting group and G'.sub.2
represents an alkoxyacetyl radical or a hydroxy-protecting group,
by replacement of the protecting group G'.sub.1 by a hydrogen atom
and optionally G'.sub.2 by a hydrogen atom and then by an
alkoxyacetyl radical, said alkoxyacetyl radical being obtained by
action of an alkoxyacetic acid or a derivative thereof on a
compound represented by the formula (I) wherein R represents a
hydrogen atom.
[0097] The radicals G'.sub.1 and G'.sub.2, when they represent a
hydroxy-protecting group are preferably
2,2,2-trichloroethoxycarbonyl or 2-(trichloromethyl-propoxy)
carbonyl radicals or trialkylsilyl, dialkylarylsilyl,
alkyldiarylsilyl or triarylsilyl radicals in which the alkyl
portions contain 1 to 4 carbon atoms and the aryl portions are
preferably phenyl radicals, it being possible, in addition, for
G'.sub.2 to represent an alkoxyacetyl radical.
[0098] When G'.sub.1 and G'.sub.2 represent a
2,2,2-trichloroethoxycarbony- l or
2-(2-trichloromethylpropoxy)carbonyl radical, the replacement of
the protecting groups by hydrogen atoms is carried out using zinc,
optionally combined with copper, in the presence of acetic acid at
a temperature ranging from 20 to 60.degree. C. or by means of an
inorganic or organic acid such as hydrochloric acid or acetic acid
in solution in an aliphatic alcohol containing 1 to 3 carbon atoms
or an aliphatic ester such as ethyl acetate, isopropyl acetate or
n-butyl acetate in the presence of zinc optionally combined with
copper.
[0099] When G'.sub.1 represents a silylated radical and G'.sub.2
represents an alkoxyacetyl radical, the replacement of the
protecting group G'.sub.1 by a hydrogen atom can be carried out by
means of, for example, gaseous hydrochloric acid in ethanolic
solution at a temperature close to 0.degree. C., under conditions
which are without effect on the rest of the molecule.
[0100] When G'.sub.2 represents an alkoxyacetyl radical, its
optional replacement by a hydrogen atom is carried out by treatment
in alkaline medium or by the action of a zinc halide under
conditions which do not affect the rest of the molecule. Generally,
the alkaline treatment is carried out by the action of ammonia in
aqueous-alcoholic medium, at a temperature close to 20.degree. C.
Generally, the treatment with a zinc halide, preferably zinc
iodide, is carried out in methanol at a temperature close to
20.degree. C.,
[0101] The product of general formula (XXV) can be obtained under
the conditions described in international application PCT/WO
9209589, the disclosure of which is incorporated by reference
herein.
[0102] The new derivatives of general formula (I) can also be
obtained by esterification of a product of general formula (VI) by
means of an acid of general formula: 25
[0103] in which Ar and R.sub.1 are defined as above and G.sub.3
represents a hydroxy-protecting group chosen from methoxymethyl,
1-ethoxyethyl, benzyloxymethyl, (.beta.-trimethylsilyloxy)methyl,
tetrahydropyranyl, 2,2,2-trichloroethoxymethyl,
2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radicals or CH.sub.2--Ph
radicals in which Ph represents a phenyl radical optionally
substituted by one or more atoms or radicals, which are identical
or different, chosen from halogen atoms and alkyl radicals
containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4
carbon atoms, or an activated derivative of this acid, to give a
product of general formula: 26
[0104] in which Ar, R.sub.1, G.sub.1, and G.sub.3 are defined as
above, followed by the replacement of the protecting group G.sub.3
by hydrogen atom and optionally G.sub.1 by a hydrogen atom and then
by an alkoxyacetyl radical, said alkoxyacetyl radical being
obtained by action of an alkoxyacetic acid or a derivative thereof
on a compound represented by the formula (I) wherein R represents a
hydrogen atom.
[0105] The esterification can be performed under the conditions
described above for the esterification of the product of general
formula (VI) by means of an acid of general formula (VII).
[0106] The replacement of the protecting groups G.sub.1 and G.sub.3
of the product of general formula (XXVII) by a hydrogen atom is
carried out by treatment with zinc, optionally combined with
copper, in the presence of acetic acid at a temperature ranging
from 30 to 60.degree. C. or by means of an inorganic or organic
acid such as hydrochloric acid or acetic acid in solution in an
aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic
ester such as ethyl acetate, isopropyl acetate or n-butyl acetate
in the presence of zinc optionally combined with copper, when
G.sub.1 and G.sub.3 represent a 2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radical. The replacement of
the protecting group G.sub.3, when it represents a silylated
radical or an acetal residue, can be carried out by treatment in
acidic medium such as for example hydrochloric acid in solution in
an aliphatic alcohol containing 1 to 3 carbon atoms (methanol,
ethanol, propanol or isopropanol) or aqueous hydrofluoric acid at a
temperature ranging from 0 to 40.degree. C., when it represents an
acetal residue, the replacement of the protecting group G.sub.1
then being carried out under the conditions described above. When
G.sub.3 represents a group --CH.sub.2--Ph, the replacement of this
protecting group with a hydrogen atom can be carried out by
hydrogenolysis in the presence of a catalyst.
[0107] The acid of general formula (XXVI) can be obtained by
saponification of an ester of general formula: 27
[0108] in which Ar, R.sub.1, R.sub.5 and G.sub.3 are defined as
above.
[0109] Generally, the saponification is carried out by means of an
inorganic base (alkali metal hydroxide, carbonate or bicarbonate)
in aqueous-alcoholic medium (methanol-water) at a temperature
ranging from 10 to 40.degree. C.
[0110] The ester of general formula (XXVIII) can be obtained
according to the usual methods for the preparation of ethers, and
more particularly according to the procedures described by J-N.
DENIS et al., J. Org. Chem., 51 46-50 (1986), from a product of
general formula (XI).
[0111] Compounds of the formula (I) 28
[0112] in which R represents an alkoxyacetyl radical, R.sub.1
represents a benzoyl radical or a radical R.sub.2--O--CO in which
R.sub.2 represents an alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl radical, and Ar
represents an aryl radical, may be made by a process comprising
esterifying a compound of the formula (XXIX): 29
[0113] in which G.sub.1 represents an alkoxyacetyl radical or other
hydroxy-protecting group and Ra represents a radical
O--SO.sub.2--CF.sub.3 or forms, together with the carbon atom of
the a methyl group, a cyclopropyl ring, with a lactam of the
formula (XXX): 30
[0114] wherein G.sub.3 is a hydroxy-protecting group chosen from
methoxymethyl, 1-ethoxyethyl, benzyloxymethyl,
(.beta.-trimethylsilyloxy)- methyl, tetrahydropyranyl,
2,2,2-trichloroethoxymethyl, 2,2,2-trichloroethoxycarbonyl or
2-(2-trichloromethylpropoxy)carbonyl radicals, or CH.sub.2--Ph
radicals in which Ph represents a phenyl radical optionally
substituted by one or more atoms or radicals, which are identical
or different, chosen from halogen atoms and alkyl radicals
containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4
carbon atoms, and Ar and R.sub.1 are defined as above, optionally
transforming the O--SO.sub.2--CF.sub.3 radical into a cyclopropyl
ring; and replacing G.sub.3 by a hydrogen atom and optionally
G.sub.1 by a hydrogen atom, said method comprising the further
step, if G.sub.1 is replaced by a hydrogen atom, of converting said
G.sub.1 hydrogen atom to an alkoxyacetyl radical by action of an
alkoxyacetic acid or derivative thereof on a compound obtained
after replacement of G.sub.1 by said hydrogen atom.
[0115] Compounds of the formula (I): 31
[0116] wherein R represents butoxyacetyl, ethoxyacetyl, and
isopropoxyacetyl, R.sub.1 represents a t-butoxycarbonyl radical,
and Ar represents phenyl, may be made by the process comprising
esterifying with an alkoxyacetic acid or derivative thereof, a
compound of the formula (II): 32
[0117] wherein G.sub.1 represents a hydrogen atom, and R.sub.3 and
R.sub.4, which are identical or different, represent a hydrogen
atom or an alkyl radical containing 1 to 4 carbon atoms, or an
aralkyl radical whose alkyl portion contains 1 to 4 carbon atoms
and the aryl portion preferably represents a phenyl radical
optionally substituted by one or more alkoxy radicals containing 1
to 4 carbon atoms, or an aryl radical preferably representing a
phenyl radical optionally substituted by one or more alkoxy
radicals containing 1 to 4 carbon atoms, or alternatively R.sub.3
represents an alkoxy radical containing 1 to 4 carbon atoms or a
trihalomethyl radical such as trichloromethyl or a phenyl radical
substituted by a trihalomethyl radical such as trichloromethyl and
R.sub.4 represents a hydrogen atom, or alternatively R.sub.3 and
R.sub.4 form, together with the carbon atom to which they are
attached, a 4- to 7-membered ring, and opening the oxazaldine ring
portoin of the compound of formula (II) to obtain the compound of
formula (I).
[0118] Compounds of the formula (I): 33
[0119] in which R represents an alkoxyacetyl radical, R.sub.1
represents a benzoyl radical or a radical R.sub.2--O--CO in which
R.sub.2 represents an alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl radical, and Ar
represents an aryl radical, may be made by a process comprising
esterifying a compound of the formula (XXIX): 34
[0120] in which G.sub.1 represents an alkoxyacetyl radical or other
hydroxy-protecting group and Ra represents a radical
O--SO.sub.2--CF.sub.3 or forms, together with the carbon atom of
the .alpha. methyl group, a cyclopropyl ring, with a free acid of
the formula (VII): 35
[0121] in which R.sub.3 and R.sub.4, which are identical or
different represent a hydrogen atom or an alkyl radical containing
1 to 4 carbon atoms, or an aralkyl radical whose alkyl portion
contains 1 to 4 carbon atoms and the aryl portion preferably
represents a phenyl radical optionally substituted by one or more
alkoxy radicals containing 1 to 4 carbon atoms, or an aryl radical
preferably representing a phenyl radical optionally substituted by
one or more alkoxy radicals containing 1 to 4 carbon atoms, or
alternatively R.sub.3 represents an alkoxy radical containing 1 to
4 carbon atoms or a trihalomethyl radical such as trichloromethyl
or a phenyl radical substituted by a trihalomethyl radical such as
trichloromethyl and R.sub.4 represents a hydrogen atom, or
alternatively R.sub.3 and R.sub.4 form, together with the carbon
atom to which they are attached, a 4- to 7-membered ring; and Ar
and R.sub.1 are defined as above, optionally transforming the
O--SO.sub.2--CF.sub.3 radical into a cyclopropyl ring, and
removing, if G.sub.1 is said other hydroxy-protecting group, said
hydroxy-protecting group to obtain a hydrogen atom and converting
said hydrogen atom to an alkoxvacetyl radical by action of an
alkoxyacetic acid or derivative thereof on said compound obtained
after replacement of said G.sub.1 hydroxy-protecting group by a
hydrogen atom.
[0122] The new products of general formula (I) obtained using the
procedures according to the invention can be purified according to
known methods such as crystallization or chromatography.
[0123] The products of general formula (I) have remarkable
biological properties.
[0124] In vitro, measurement of the biological activity is carried
out on tubulin extracted from pig brain by the method of M. L.
Shelanski et al., Proc. Natl. Acad. Sci. USA, 70, 765-768 (1973).
The study of the depolymerization of the microtubules into tubulin
is carried out according to the method of G. Chauvire et al., C.R.
Acad. Sci., 293, srie II, 501-503 (1981). In this study, the
products of general formula (I) proved at least as active as taxol
and Taxotere.
[0125] In vivo, the products of general formula (I) proved active
in mice grafted with the B16 melanoma at doses ranging from 1 to 10
mg/kg intraperitoneally, as well as on other liquid or solid
tumours.
[0126] The new compounds have anti-tumor properties, more
particularly, activity against tumors which are resistant to
Taxol.RTM. and Taxotere.RTM.. Such tumors include, for example,
colon tumors which have an elevated expression of mdr 1 gene
(multi-rug resistant gene). Multi-drug resistance is the usual term
relating to the resistance by a tumor against various compounds
having differing structures and mechanisms of action. Taxoids are
generally known to be highly recognized by experimental tumors such
as P388/DOX, a P388 murine leukemia cell line selected for
doxorubicin (DOC) resistance, which express mdr 1. The new
compounds according to the present invention are less recognized by
P388/DOX. More particularly, the new compounds are less recognized
than Taxotere.RTM. by mdr 1.
[0127] In particular, it has been found that the new compounds of
the present invention including the compounds of example 1, example
2 and example 3 have better multi-drug resistance properties than
Taxol.RTM. and Taxotere.RTM.. Additionally, it has surprisingly
been found that the compound of example 3 has substantially better
multi-drug resistance properties than the compounds of example 1
and example 2.
[0128] The following Examples 1-5 provide general illustration and
Examples 6-10 illustrate the present invention:
EXAMPLE 1
[0129] A solution of 2.01 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-ep-
oxy-1.beta.,10.beta.-dihydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-t-
axen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-ox-
azolidinecarboxylate in 20 cm.sup.3 of formic acid is stirred for 4
hours at a temperature close to 20.degree. C. and then concentrated
to dryness under reduced pressure (0.27 kPa) at 40.degree. C. The
foam obtained is dissolved in 100 cm.sup.3 of dichloromethane and
the solution obtained is supplemented with 20 cm.sup.3 of a
saturated aqueous sodium hydrogen carbonate solution. The aqueous
phase is separated after settling has taken place and extracted
with 20 cm.sup.3 of dichloromethane. The organic phases are pooled,
dried over magnesium sulphate, filtered and then concentrated to
dryness under reduced pressure (2.7 kPa) at 40.degree. C. 1.95 g of
a white foam are obtained which are purified by chromatography on
200 g of silica (0.063-0.2 mm) contained in a column 7 cm in
diameter, eluting with a dichloromethane-methanol mixture (98-2 by
volume) and collecting 30 cm.sup.3 fractions. The fractions
containing only the desired product are pooled and concentrated to
dryness under reduced pressure (0.27 kPa) at 40.degree. C. for 2
hours. 1.57 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.,10.beta.-dihydroxy-
-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,3S)-3-amino-2-hydroxy-3-phenylpropionate are obtained in the
form of a white Foam.
[0130] To a solution of 400 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-
-epoxy-1.beta.,10.beta.-dihydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-1-
1-taxen-13.alpha.-yl (2R,3S)-3-amino-2-hydroxy-3-phenylpropionate
in 1 cm.sup.3 of dichloromethane, kept under an argon atmosphere,
are added 60 mg of sodium hydrogen carbonate and then, dropwise, at
a temperature close to 20.degree. C., a solution of 0.16 g of
di-tert-butyl dicarbonate in 1 cm.sup.3 of dichloromethane. The
solution obtained is stirred for 64 hours at a temperature close to
20.degree. C. and then supplemented with a mixture of 5 cm.sup.3 of
distilled water and 10 cm.sup.3 of dichloromethane. The organic
phase is washed with three times 2 cm.sup.3 of distilled water. The
organic phase is dried over magnesium sulphate, filtered and then
concentrated to dryness under reduced pressure (2.7 kPa) at
40.degree. C. 317 mg of a white foam are thus obtained which are
purified by chromatography on 30 g of silica (0.063-0.2 mm)
contained in a column 3 cm in diameter, eluting with a
dichloromethane-methanol mixture (95-5 by volume) and collecting 5
cm.sup.3 fractions. The fractions containing only the desired
product are pooled and concentrated to dryness under reduced
pressure (0.27 kPa) at 40.degree. C. for 2 hours. 161 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.,1-
0.beta.-dihydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha-
.-yl (2R,
3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate are
thus obtained in the form of a white foam whose characteristics are
the following:
[0131] specific rotation: [.alpha.].sub.D.sup.20=-17.degree.
(c=0.482; methanol)
[0132] proton NMR spectrum: (400 MHz; CDCl.sub.3; temperature of
323 K; .delta. in ppm; coupling constants J in Hz):1.21 (s,
3H:--CH.sub.3 16 or 17); 1.28 (s, 3H:--CH.sub.3 16 or 17); 1.34 [s,
9H:--C(CH.sub.3).sub.3]; from 1.30 to 1.50 (mt, 1H:--H7); 1.80 and
2.36 (2mt, 1H each:--CH.sub.2-- of cyclopropane); 1.88 (s,
3H:--CH.sub.3 18); 2.13 [mt, 1H:--(CH)--H6]; 2.26 [dd, 1H, J=15 to
8.5:--(CH)--H 14]; 2.35 (s, 3H:--COCH.sub.3); from 2.35 to 2.50
[mt, 2H:--(CH) --H 14 and --(CH)--H 6]; 3.21 (d, 1H, J=4:--OH 2');
4.08 [d, 1H, J=8:--(CH)--H 20]; 4.16 (d, 1H, J=7: --H 3); 4.18 (s,
1H, --OH 10); 4.31 [d, 1H, J=8:--(CH)--H20]:4.61 (dd, 1H, J=4 and
2:--H2'); 4.74 (d, 1H, J=4:--H 5); 5.00 (s, 1H:--H 10); 5.26 (dd,
1H, J=9 and 2:--H 3'); 5.33 (d, 1H, J=9:--NH3'); 5.69 (d, 1H,
J=7:--H 2); 6.29 (d, 1H, J=8.5:--H13); from 7.30 to 7.50 [mt,
5H:--C.sub.6H.sub.5 in 3' (--H 2 to --H 6); 7.51 [t, 2H,
J=7.5:--OCOC.sub.6H.sub.5 (--H 3 to H 5)]; 7.60 [t, 1H,
J=7.5:--OCOC.sub.6H.sub.5 (--H 4)]; 8.14 [d, 2H,
J=7.5:--OCOC.sub.6H.sub.5 (--H 2 and H 6)].
[0133] The
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.,10.beta.-
-dihydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxyl-
ate can be prepared in the following manner:
[0134] To a solution of 2.5 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20--
epoxy-1.beta.,10.beta.-dihydroxy-9-oxo-7.beta.-trifluoromethanesulphonate--
11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl--
5-oxazolidinecarboxylate in 25 cm.sup.3 of anhydrous acetonitrile
and 3 cm.sup.3 of anhydrous tetrahydrofuran, kept under an argon
atmosphere, are added 2.5 g of sodium azide. The reaction mixture
is heated for 2 hours, with stirring and under an argon atmosphere
at a temperature close to 80.degree. C., then cooled to a
temperature close to 20.degree. C. and supplemented with 30
cm.sup.3 of distilled water. The aqueous phase is separated by
decantation and then extracted with 20 cm.sup.3 of dichloromethane.
The combined organic phases are dried over magnesium sulphate,
filtered and then concentrated to dryness under reduced pressure
(2.7 kPa) at 40.degree. C. 2.44 g of a yellow foam are thus
obtained which are purified by chromatography on 300 g of silica
(0.063-0.2 mm) contained in a column 8 cm in diameter, eluting with
a dichloromethane-ethyl acetate mixture (90-10 by volume) and
collecting 60 cm.sup.3 fractions. Fractions 47 to 70 are pooled and
concentrated to dryness under reduced pressure (0.27 kPa) at
40.degree. C. for 2 hours. 2.01 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.,
10.beta.-dihydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alp-
ha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidineca-
rboxylate are thus obtained in the form of a white foam.
[0135] The
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.,10.beta.-
-dihydroxy-9-oxo-7.beta.-trifluoromethanesulphonate-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxyl-
ate can be prepared in the following manner:
[0136] To a solution of 2.86 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-
-epoxy-1.beta.,7.beta.,10.beta.-trihydroxy-9-oxo-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxyl-
ate in 29 cm.sup.3 of anhydrous dichloromethane, kept under an
argon atmosphere, are added 0.955 cm.sup.3 of pyridine and 50 mg of
powdered activated 4 .ANG. molecular sieve. The reaction mixture is
cooled to a temperature close to -35.degree. C., slowly
supplemented with 0.85 cm.sup.3 of trifluoromethanesulphonic
anhydride, stirred at a temperature close to -5.degree. C. for 15
minutes and supplemented with 10 cm.sup.3 of distilled water. After
filtration on sintered glass provided with celite and rinsing off
the sintered glass with 3 times 10 cm.sup.3 of a
methanol-dichloromethane mixture (10-90 by volume), the aqueous
phase is separated after settling has taken place and extracted
with twice 10 cm.sup.3 of dichloromethane. The organic phases are
pooled, dried over magnesium sulphate, filtered and then
concentrated to dryness under reduced pressure (2.7 kPa) at
40.degree. C. 3.87 g of a white foam are obtained which are
purified by chromatography on 400 g of silica (0.063-0.2 mm)
contained in a column 10 cm in diameter, eluting with a
dichloromethane-ethyl acetate gradient (from 97.5-2.5 to 90-10 by
volume) and collecting 80 cm.sup.3 fractions. The fractions
containing only the desired product are pooled and concentrated to
dryness under reduced pressure (0.27 kPa) at 40.degree. C. for 2
hours. 3.0 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.,10.beta.-dihydroxy-
-9-oxo-7.beta.-trifluoromethanesulphonate-11-taxen-13.alpha.-yl(4S,5R)-3-t-
ert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate
are thus obtained in the form of a white foam.
[0137] The
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.,7.beta.,-
10.beta.-trihydroxy-9-oxo-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbo-
nyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate can be prepared
in the following manner:
[0138] A solution of 24.35 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,
20-epoxy-9-oxo-7.beta.,10.beta.-[bis(2,2,2-trichloroethoxy)carbonyloxy]-1-
.beta.-hydroxy-11-taxen-13.alpha.-yl(4S,5R)-3-tert-butoxycarbonyl-2,2-dime-
thyl-4-phenyl-5-oxazolidinecarboxylate in a mixture of 130 cm.sup.3
of ethyl acetate and 46.5 cm.sup.3 of acetic acid is heated, with
stirring and under an argon atmosphere up to a temperature close to
60.degree. C. and then supplemented with 40 g of zinc powder. The
reaction mixture is then stirred for 30 minutes at 60.degree. C.
and then cooled to a temperature close to 20.degree. C. and
filtered on sintered glass provided with celite. The sintered glass
is washed with 100 cm.sup.3 of a methanol-dichloromethane mixture
(20-80 by volume); the filtrates are pooled and then concentrated
to dryness under reduced pressure (0.27 kPa) at a temperature close
to 40.degree. C.
[0139] The residue is supplemented with 500 cm.sup.3 of
dichloromethane. The organic phase is washed with twice 50 cm.sup.3
of a saturated aqueous sodium hydrogen carbonate solution and then
with 50 cm.sup.3 of distilled water. The aqueous phases obtained
after settling has taken place and pooled are extracted with twice
30 cm.sup.3 of dichloromethane. The organic phases are pooled,
dried over magnesium sulphate, filtered and then concentrated to
dryness under reduced pressure (2.7 kPa) at 40.degree. C. 19.7 g of
a white foam are obtained which are purified by chromatography on
800 g of silica (0.063-0.2 mm) contained in a column 10 cm in
diameter, eluting with a dichloromethane-methanol gradient (from
100-0 to 97-3 by volume) and collecting 80 cm.sup.3 fractions. The
fractions containing only the desired product are pooled and
concentrated to dryness under reduced pressure (0.27 kPa) at
40.degree. C. for 2 hours. 16.53 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.,-
7.beta.,10.beta.-trihydroxy-9-oxo-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxyl-
ate in the form of a white foam.
[0140] The
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-9-oxo-7.beta.,10-
.beta.-[bis(2,2,2-trichloroethoxy)carbonyloxy]-1.beta.-hydroxy-11-taxen-13-
.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidi-
necarboxylate can be prepared according to the method described in
international application PCT WO 9209589.
EXAMPLE 2
[0141] To a solution of 550 mg of
4.alpha.,10.beta.-diacetoxy-2.alpha.-ben-
zoyloxy-5.beta.,20-epoxy-1.beta.-hydroxy-7.beta.,8.beta.-methylene-9-oxo-1-
9-nor-11-taxen-13.alpha.-yl
(2R,3S)-3-amino-2-hydroxy-3-phenylpropionate are added 45 cm.sup.3
of distilled water, 45 cm.sup.3 of a saturated aqueous sodium
hydrogen carbonate solution and then, dropwise, at a temperature
close to 20.degree. C., 0.096 cm.sup.3 of benzoyl chloride. The
mixture obtained is stirred for 10 minutes at a temperature close
to 20.degree. C. After settling has taken place, the aqueous phase
is extracted with twice 30 cm.sup.3 of ethyl acetate. The combined
organic phases are dried over magnesium sulphate, filtered and then
concentrated to dryness under reduced pressure (2.7 kPa) at
40.degree. C. 670 mg of a white foam are thus obtained which are
purified by chromatography at atmospheric pressure on 50 g of
silica (0.063-0.2 mm) contained in a column 2.5 cm in diameter,
eluting with a methanol-dichloromethane mixture (1-99 then 2.5-97.5
by volume) and collecting 10 cm.sup.3 fractions. The fractions
containing only the desired product are pooled and concentrated to
dryness under reduced pressure (2.7 kPa) at 40.degree. C. 610 mg of
a white foam are thus obtained. A sample of 300 mg is purified by
preparative chromatography on 12 thin-layer silica plates
(Kieselgel 60F254, Merck; thickness 0.25 mm), eluting with a
methanol-dichloromethane mixture (3-97 by volume). After elution of
the zone corresponding to the main product with a
methanol-dichloromethane mixture (10-90 by volume) and then
evaporation of the solvents under reduced pressure (0.27 kPa) at a
temperature close to 40.degree. C., 155.2 mg of
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-ep-
oxy-1.beta.-hydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alp-
ha.-yl (2R,3S)-3-benzoylamino-2-hydroxy-3-phenylpropionate are
obtained in the form of a white foam whose characteristics are the
following:--specific rotation: [.alpha.].sub.D.sup.20=-30.5.degree.
(c=0.491; methanol)
[0142] proton NMR spectrum: (300 MHz; CDCl.sub.3; .delta. in ppm;
coupling constants J in Hz):1.27 (s, 3H: --CH.sub.3 16 or 17); 1.30
(s, 3H: --CH.sub.3 16 or 17); 1.40 (mt, 1H: --H7); 1.62 and 2.25 (q
and m, 1H each: CH.sub.3-- of cyclopropane); 1.85 (s, 3H:
--CH.sub.3 18); 1.96 (s, 1H: --OH in 1); 2.05 and 2.48 (d and m, 1H
each: --CH.sub.3-- in 6); 2.24 (s, 3H: --COCH.sub.3 in 10); 2.28
and 2.50 (m, 1H each: --CH.sub.3 in 14); 2.45 (s, 3H: --COCH.sub.3
in 4); 3.52 (d, 1H: --OHin 2'); 4.10 and 4.35 (d, 1H each: --CH in
20); 4.11 (d, 1H: --H3); 4.77 (broad d, 1H: --H5); 4.82 (dd, 1H:
--H2'); 5.70 (d, 1H: --H in 2); 5.84 (dd, 1H: --H3'); 6.30 (broad
t, 1H: --H13); 6.36 (s, 1H: --H10); 7.00 (d, 1H: --CONH--); from
7.35 to 8.30 (m, 15H: --C.sub.6H.sub.5 in 3', --OCOC.sub.6H.sub.5
and NHCOC.sub.6H.sub.5) .
[0143] The
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-epox-
y-1.beta.-hydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha-
.-yl (2R,3S)-3-amino-2-hydroxy-3-phenylpropionate can be prepared
by carrying out the procedure under the conditions described in
Example 1 for the preparation of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.b-
eta.,10.beta.-dihydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13-
.alpha.-yl (2R,3S)-3-amino-2-hydroxy-3-phenylpropionate. Thus,
starting with 1.6 g of
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20--
epoxy-1.beta.-hydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.a-
lpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinc-
arboxylate, 1.14 g of
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.be-
ta.,20-epoxy-1.beta.-hydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-tax-
en-13.alpha.-yl are obtained in the form of a white foam.
[0144] The
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-epox-
y-1.beta.-hydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha-
.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidincarbo-
xylate can be prepared under the conditions described in Example 1
for the preparation of
4.alpha.-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.be-
ta.,10.beta.-dihydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.-
alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidin-
ecarboxylate. Thus, starting with 2.2 g of
4.alpha.,10.beta.-diacetoxy-2.a-
lpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.-hydroxy-9-oxo-7.beta.-trifluorom-
ethanesulphonate-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-d-
imethyl-4-phenyl-5-oxazolidincarboxylate, 1.62 g of
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.--
hydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidincarboxyla-
te are obtained in the form of a white foam.
[0145] The
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-epox-
y-1.beta.-hydroxy-9-oxo-7.beta.-trifluoromethanesulphonate-11-taxen-13.alp-
ha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidineca-
rboxylate can be prepared under the conditions described in Example
1 for the preparation of
4.alpha.-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy--
1.beta.,10.beta.-dihydroxy-9-oxo-7.beta.-trifluoromethanesulphonate-19-nor-
-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-
-5-oxazolidinecarboxylate. Thus, starting with 2.4 g of
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.,-
7.beta.-dihydroxy-9-oxo-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbony-
l-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate, 2.46 g of
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.--
hydroxy-9-oxo-7.beta.-trifluoromethanesulphonate-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxyl-
ate are obtained in the form of a white foam.
[0146] The
4.alpha.,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-epox-
y-1.beta.,7.beta.-dihydroxy-9-oxo-11-taxen-13.alpha.-yl
(4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxyl-
ate can be prepared under the conditions described in International
Application PCT WO 9209589.
EXAMPLE 3
[0147] To a solution of 550 mg of
4.alpha.,10.beta.-diacetoxy-2.alpha.-ben-
zoyloxy-5.beta.,20-epoxy-1.beta.-hydroxy-7.beta.,8.beta.-methylene-9-oxo-1-
9-nor-11-taxen-13.alpha.-yl
(2R,3S)-3-amino-2-hydroxy-3-phenylpropionate in 1 cm.sup.3 of
dichloromethane, kept under an argon atmosphere, are added 76 mg of
sodium hydrogen carbonate and then, dropwise, at a temperature
close to 20.degree. C., a solution of 197 mg of di-tert-butyl
dicarbonate in 1 cm.sup.3 of dichloromethane. The solution obtained
is stirred for 15 hours at a temperature close to 20.degree. C. and
then supplemented with a mixture of 5 cm.sup.3 of distilled water
and 10 cm.sup.3 of dichloromethane. The aqueous phase is extracted
with 5 cm.sup.3 of dichloromethane. The combined organic phases are
dried over magnesium sulphate, filtered and then concentrated to
dryness under reduced pressure (2.7 kPa) at 40.degree. C. 780 mg of
a white foam are thus obtained which are purified by chromatography
at atmospheric pressure on 50 g of silica (0.063-0.2 mm) contained
in a column 2.5 cm in diameter, eluting with a
methanol-dichloromethane mixture (1-99 then 2.5-97.5 by volume) and
collecting 10 cm.sup.3 fractions. The fractions containing only the
desired product are pooled and concentrated to dryness under
reduced pressure (2.7 kPa) at 40.degree. C. 660 mg of a white foam
are thus obtained. A sample of 300 mg is purified by preparative
chromatography on 12 thin-layer silica plates (Kieselgel 60F254,
Merck; thickness 0.25 mm), eluting with a methanol-dichloromethan-
e mixture (4-96 by volume). After elution of the zone corresponding
to the main product with a methanol-dichloromethane mixture (10-90
by volume) and then evaporation of the solvents under reduced
pressure (0.27 kPa) at a temperature close to 40.degree. C., 159.7
mg of 4.alpha.,10.beta.-diace-
toxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.-hydroxy-7.beta.,8.beta.--
methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,3S)-3-tert-butoxycarbonyl- amino-2-hydroxy-3-phenylpropionate
are obtained in the form of a white foam whose characteristics are
the following:
[0148] specific rotation: [.alpha.].sub.D.sup.20=-34.degree.
(c=0.564; methanol)
[0149] proton NMR spectrum: (400 MHz; CDCl.sub.3; .delta. in ppm;
coupling constants J in Hz): 1.28 (s, 3H: --CH.sub.3 16 or 17);
1.30 [s, 9H: --C(CH.sub.3).sub.3]; 1.38 (mt, 1H: --H7); 1.60 (s,
3H; --CH.sub.3 16 or 17); 1.68 and 2.25 (t and m, 1H each;
CH.sub.3-- of cyclopropane); 1.85 (s, 3H: --CH.sub.3 18); 2.10 and
2.45 (d and td, 1H each: --CH.sub.3-- in 6); 2.23 (s, 3H:
--COCH.sub.3 in 10); 2.22 and 2.40 (m, 1H each: --CH.sub.2-- in
14); 2.40 (s, 3H: --COCH.sub.3 in 4); 3.28 (d, 1H: --OH in 2');
4.05 and 4.22 (d, 1H each: --CH-- in 20); 4.10 (d, 1H: --H3); 4.62
(broad s, 1H: --H2'); 4.73 (d, 1H: --H5); 5.29 (broad d, 1H:
--H3'); 5.37 (d, 1H: --CONH--); 5.67 (d, 1H: --H in 2); 6.28 (broad
t, 1H: --H13); 6.33 (s, 1H: --H10); from 7.30 to 7.45 (mt, 5H:
--C.sub.6H.sub.5 in 3'); 7.51 [t, 2H: --OCOC.sub.6H.sub.5 (--H3 and
--H5)]; 7.61 [t, 1H: --OCOC.sub.6H.sub.5 (--H4)]; 8.17 [d, 2H:
--OCOC.sub.6H.sub.5 (--H2 and --H6)].
EXAMPLE 4
[0150] To a solution of 100 mg of 10-deacetyl-baccatin III in a
mixture of 3 cm.sup.3 of tetrahydrofuran and 0.05 cm.sup.3 of
pyridine cooled to a temperature close to -78.degree. C. and kept
under an argon atmosphere, is added, dropwise, 0.09 cm.sup.3 of
trifluoromethanesulphonic anhydride. The temperature is allowed to
rise slowly to a temperature close to 0.degree. C. over
approximately one hour, then up to a temperature close to
20.degree. C. over approximately one hour. After 2 hours at a
temperature close to 20.degree. C., 200 mg of tetrabutylammonium
iodide are added, then the solution is heated at the boiling
temperature of the solvent for 15 hours. After cooling to a
temperature close to 20.degree. C., 10 cm.sup.3 of ethyl acetate
and then 1 cm.sup.3 of distilled water are added. After separation
after settling has taken place, the organic phase is dried over
magnesium sulphate, filtered and concentrated to dryness under
reduced pressure (2.7 kPa) at 40.degree. C. 116 mg of a yellow oil
are thus obtained which are purified by chromatography at
atmospheric pressure on 30 g of silica (0.063-0.2 mm) contained in
a column 2.5 cm in diameter, eluting with an ethyl
acetate-dichloromethane mixture, with an elution gradient from
0-100 to 80-20 by volume. The fractions containing the desired
product are pooled and concentrated to dryness under reduced
pressure (0.27 kPa) at 40.degree. C. 10.3 mg of
10-deacetyl-7.beta.,8.beta.-methylene-19-norbaccatin III are thus
obtained in the form of a white foam whose characteristics are the
following:
[0151] proton NMR spectrum: (400 MHz; CDCl.sub.3; .delta. in ppm;
coupling constants J in Hz): 1.14 (s, 3H: --CH.sub.3 in 16 or 17);
1.42 (mt, 1H: --H in 7); 1.76 and 2.31 (t and m, 1H each; CH.sub.2
of cyclopropane); 2.07 (s, 3H; --CH.sub.3 in 18); 2.15 and 2.50
(broad d and td, 1H each: CH.sub.2-- in 6); 2.30 (s, 3H:
--COCH.sub.3 in 4); 2.28 and 2.35 (m, 1H each: --CH.sub.2 in 14);
4.11 and 4.37 (d, 1H each: --CH.sub.2 in 20); 4.28 (d, 1H: --H3 in
3); 4.79 (d, 1H: --H in 5); 4.88 (broad t, 1H: --H in 13); 5.09 (s,
1H: --Hin 10); 5.66 (d, 1H: --H in 2); 7.51 [t, 2H:
--OCOC.sub.6H.sub.5 (--H in 3 and 5)]; 7.61 [t, 1H:
--OCOC.sub.6H.sub.5 (--H in 4)]; 8.17 [d, 2H: --OCOC.sub.6H.sub.5
(--H in 2 and 6)].
[0152] .sup.13C NMR spectrum: (100 MHz; CDCl.sub.3; .delta. in ppm;
uncoupled; s=singlet, d=doublet; t=triplet; q=quadruplet): 15 (q,
C18); 16.5 (t, C19); 20 and 27 (q, C16 and C17); 22.5 (q,
--COCH.sub.3); 26.5 (t, C6); 33 (d, C7); 35 (s, C8); 39 (d, C3);
39.5 (t, C14); 43 (s, C15); 68 (d, C13); 76 (t, C20); 76.2 (d,
C10); 79.5 (s, C1); 80 (s, C4); 81 (d, C2); 85 (d, C5); 129 (d, C2:
--OCOC.sub.6H.sub.5); 130 (s, Cl of --OCOC.sub.6H.sub.5); 130.5 (d,
C3 of --OCOC.sub.6H.sub.5); 134 (d, C4 of --OCOC.sub.6H.sub.5); 136
(s, C11); 143 (s, C12); 168 (s, --OCOC.sub.6H.sub.5); 171 (s,
--COCH.sub.3); 210 (s, C9).
[0153] The new products of general formula (I) manifest a
significant inhibitory activity with respect to abnormal cell
proliferation and possess therapeutic properties which permit the
treatment of patients having pathological conditions associated
with abnormal cell proliferation. The pathological conditions
include the abnormal cell proliferation of malignant or
nonmalignant cells of various tissues and/or organs, comprising,
with no limitation being implied, muscle, bone or connective
tissues, the skin, brain, lungs, sex organs, the lymphatic or renal
systems, mammary or blood cells, liver, the digestive tract,
pancreas and thyroid or adrenal glands. These pathological
conditions can also include psoriasis, solid tumours, cancers of
the ovary, breast, brain, prostate, colon, stomach, kidney or
testicles, Kaposi's sarcoma, cholangioma, chorioma, neuroblastoma,
Wilms' tumour, Hodgkin's disease, melanomas, multiple myelomas,
lymphatic leukemias and acute or chronic granulocytic lymphomas.
The new products according to the invention are particularly useful
for the treatment of cancer of the ovary. The products according to
the invention can be used to prevent or retard the appearance or
reappearance of the pathological conditions or to treat these
pathological conditions.
[0154] The products according to the invention can be administered
to a patient in various forms adapted to the chosen route of
administration which is preferably the parenteral route. Parenteral
administration comprises intravenous, intraperitoneal,
intramuscular or subcutaneous administrations. Intraperitoneal or
intravenous administration is more particularly preferred.
[0155] The present invention also comprises pharmaceutical
compositions containing at least one product of general formula (I)
in a sufficient quantity adapted to use in human or veterinary
therapy. The compositions can be prepared according to the
customary methods, using one or more pharmaceutically acceptable
adjuvants, carriers or excipients. Suitable carriers include
diluents, sterile aqueous media and various nontoxic solvents.
Preferably, the compositions are provided in the form of aqueous
solutions or suspensions, of injectable solutions which may contain
emulsifying agents, colorants, preservatives or stabilizers.
[0156] The choice of adjuvants or excipients may be determined by
the solubility and the chemical properties of the product, the
particular mode of administration and good pharmaceutical
practice.
[0157] For parenteral administration, aqueous or nonaqueous sterile
solutions or suspensions are used. For the preparation of
nonaqueous solutions or suspensions, natural vegetable oils such as
olive oil, sesame oil or paraffin oil or injectable organic esters
such as ethyl oleate can be used. The aqueous sterile solutions may
consist of a solution of a pharmaceutically acceptable salt in
solution in water. The aqueous solutions are suitable for
intravenous administration insofar as the pH is appropriately
adjusted and isotonicity is achieved, for example, with a
sufficient quantity of sodium chloride or glucose. The
sterilization can be performed by heating or by any other means
which does not adversely affect the composition.
[0158] It is clearly understood that all the products entering into
the compositions according to the invention should be substantially
pure and nontoxic for the quantities used.
[0159] The compositions may contain at least 0.01% of
therapeutically active product. The quantity of active product in a
composition is such that a suitable dosage can be prescribed.
Preferably, the compositions are prepared such that a single dose
contains about 0.01 to 1000 mg of active product for parenteral
administration.
[0160] The therapeutic treatment can be performed concurrently with
other therapeutic treatments including antineoplastic drugs,
monoclonal antibodies, immunotherapies or radiotherapies or
biological response modifiers. The response modifiers include, with
no limitation being implied, lymphokines and cytokines such as
interleukins, interferons (.alpha., .beta. or .delta.) and TNF.
Other chemotherapeutic agents which are useful in the treatment of
disorders caused by abnormal proliferation of cells include, with
no limitation being implied, alkylating agents like nitrogen
mustards such as mechloretamine, cyclophosphamide, melphalan and
chlorambucil, alkyl sulphonates such as busulfan, nitrosoureas such
as carmustine, lomustine, semustine and streptozocin, triazenes
such as dacarbazine, antimetabolites such as folic acid analogues
like methotrexate, pyrimidine analogues such as fluorouracil and
cytarabine, purine analogues such as mercaptopurine and
thioguanine, natural products like vinca alkaloids such as
vinblastine, vincristine and vindesine, epipodophyllotoxins such as
etoposide and teniposide, antibiotics such as dactinomycin,
daunorubicin, doxorubicin, bleomycin, plicamycin and mitomycin,
enzymes such as L-asparaginase, various agents such as coordination
complexes of platinum like cisplatin, substituted ureas like
hydroxyurea, methylhydrazine derivatives such as procarbazine,
adrenocortical suppressants such as mitotane and aminoglutethymide,
hormones and antagonists such as adrenocorticosteroids such as
prednisone, progestins such as hydroxyprogesterone caproate,
methoxyprogesterone acetate and megestrol acetate, oestrogens such
as diethylstilbestrol and ethynylestradiol, antioestrogens such as
tamoxifen, and androgens such as testosterone propionate and
fluoroxymesterone.
[0161] The doses used for carrying out the methods according to the
invention are those which permit a prophylactic treatment or a
maximum therapeutic response. The doses vary according to the form
of administration, the particular product selected and the
characteristics specific to the subject to be treated. In general,
the doses are those which are therapeutically effective for the
treatment of disorders caused by abnormal cell proliferation. The
products according to the invention can be administered as often as
necessary to obtain the desired therapeutic effect. Some patients
may respond rapidly to relatively high or low doses, and then
require low or zero maintenance doses. Generally, low doses will be
used at the beginning of the treatment and, if necessary,
increasingly higher doses will be administered until an optimum
effect is obtained. For other patients, it may be necessary to
administer maintenance doses 1 to 8 times per day, preferably 1 to
4 times according to the physiological needs of the patient
considered. It is also possible that for certain patients it may be
necessary to use only one to two daily administrations.
[0162] In man, the doses are generally range from 0.01 to 200
mg/kg. For intraperitoneal administration, the doses will generally
range from 0.1 to 100 mg/kg and, preferably, from 0.5 to 50 mg/kg
and, still more specifically, from 1 to 10 mg/kg. For intravenous
administration, the doses are generally range from 0.1 to 50 mg/kg
and, preferably, from 0.1 to 5 mg/kg and, still more specifically,
from 1 to 2 mg/kg. It is understood that, in order to choose the
most appropriate dosage, account should be taken of the route of
administration, the patient's weight, his general state of health,
his age and all factors which may influence the efficacy of the
treatment.
[0163] The following example is generally illustrative.
EXAMPLE 5
[0164] 40 mg of the product obtained in Example 1 are dissolved in
1 cm.sup.3 of Emulphor EL 620 and 1 cm.sup.3 of ethanol and then
the solution is diluted by addition of 18 cm.sup.3 of physiological
saline.
[0165] The composition is administered by perfusion for 1 hour by
introduction into physiological saline.
EXAMPLE 6
[0166] To a solution of 1.2 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20--
epoxy-1-hydroxy-10.beta.-methoxyacetoxy-7.beta.-trifluoromethanesulphonylo-
xy-9-oxo-11-taxen-13.alpha.-yl
(2R,3S)-3-tert-butoxycarbonylamino-2-hydrox-
y-(3-thienyl)propionate in a mixture of 15 cm.sup.3 of anhydrous
acetonitrile and 1.5 cm.sup.3 of anhydrous tetrahydrofuran, under
argon atmosphere, are added 0.6 g of powdered 4.ANG. molecular
sieve and 1.8 g of sodium chloride. The reaction mixture is stirred
at 20.degree. C. for 30 minutes, then heated at the boiling
temperature of the solvent for 2 hours. After cooling at 20.degree.
C., 50 cm.sup.3 of dichloromethane are added and the reaction
mixture is filtered on a sintered glass filter. The filter is
washed with twice 20 cm.sup.3 of dichloromethane and the pooled
filtrates are washed with twice 20 cm.sup.3 of water, dried over
sodium sulphate, filtered and concentrated at 40.degree. C. under
reduced pressure (2.7 kPa). 925 mg of a white amorphous solid are
obtained which are purified by chromatography on 100 g silica gel
(0.063-0.2 mm) contained in a column 3 cm in diameter, eluting with
a dichloromethane-methanol mixture (99-10 by volume)and collecting
25 cm.sup.3 fractions. Fractions 16 and 26 are pooled and
concentrated to dryness under reduced pressure (2.7 kPa) at
40.degree. C. for 16 hours. 217 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.bet-
a.-methoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor
11-taxen-13.alpha.-yl
(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-(3-thi- enyl)
propionate are thus obtained in the form of a white amorphous solid
whose characteristics are the following:
[0167] specific rotation: [.alpha.].sub.D.sup.20=-28 (c=0.37;
methanol)
[0168] proton NMR spectrum (400 MHz; CDCl.sub.3;.delta. in ppm;
coupling constants J in Hz): 1.25 (s, 3H: CH.sub.3); 1.27 (s, 3H:
CH.sub.3); 1.31 (s, 9H: C(CH.sub.3).sub.3); 1.40 (m, 1H: H 7);
1.69, 2.20 to 2.35 (2m, 1H each: CH.sub.2 19); 1.84 (s, 1H: OH 1);
1.87 (s, 3H: CH.sub.3); 2.11, 2.35 to 2.50 (respectively: broad d,
J=16, and m, 1H each: CH.sub.2 6); 2.20 to 2.50 (m, 2H: CH.sub.2
14); 2.37 (s, 3H: COCH.sub.3); 3.30 (m, 1H: OH 2'); 3.52 (s, 3H:
OCH.sub.3); 4.04 and 4.30 (2d,J=9, 1H each: CH.sub.2 20); 4.10
(d,J=7, 1H: H 3); 4.21 (AB limit, J=16, 2H: OCOCH.sub.2O); 4.62 (m,
1H: H 2'); 4.72 (m, 1H: H 5); 5.20 (d,J=10, 1H: CONH); 5.34 (m, 1H:
H 3'); 5.68 (d,J=7, 1H: H 2); 6.26 (broad t, J=9, 1H: H 13); 6.41
(s, 1H: H 10); 7.10 (d,J=4, H-4 thienyl); 7.28 (m, 1H: H-2
thienyl); 7.37 (dd, J=4 and 3.5, 1H: H-5 thienyl); 7.51 (t, J=7.5,
2H: OCOC.sub.6H.sub.5 H-meta); 7.61 (t, J=7.5, 1H:
OCOC.sub.6H.sub.5 H-para); 8.15 (d, J=7.5, 2H: OCOC.sub.6H.sub.5
H-ortho).
[0169]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-m-
ethoxyacetoxy-7.beta.-trifluoromethanesulphonyloxy-9-oxo-11-taxen-13.alpha-
.-yl
(2R,3S)-3-tert-butoxycarbonylamino-2-(1-ethoxyethoxy)-3-(3-thienyl)pr-
opionate can be prepared in the following way:
[0170] To a solution of 1.12 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-
-epoxy-1,13.alpha.-dihydroxy-10.beta.-methoxyacetoxy-7.beta.-trifluorometh-
anesulphonyloxy-9-oxo-11-taxene in 75 cm.sup.3 of anhydrous
tetrahydrofuran, under argon atmosphere, are added 0.80 g of
(3R,4S)-1-(tert-butoxycarbonyl)-3-(1-ethoxyethoxy)-4-(3-thienyl)-2-azetid-
inone at 20.degree. C. The reaction mixture is cooled at
-30.degree. C. and 2 cm.sup.3 of a 2M solution of sodium
bis(trimethylsilyl)amide in tetrahydrofuran are added dropwise
while the temperature is maintained at -30.degree. C. The reaction
mixture is cooled at -30.degree. C. for 30 minutes, then warmed at
20.degree. C. A mixture of 50 cm.sup.3 of a saturated aqueous
ammonium chloride solution and 50 cm.sup.3 of water is added. The
mixture is extracted with twice 150 cm.sup.3 dichloromethane. The
organic phases are pooled, washed with 3 times 75 cm.sup.3 water,
dried over sodium sulphate, filtered and concentrated to dryness
under reduced pressure (2.7 kPa) at 40.degree. C. 1.75 g of a pale
yellow amorphous solid are obtained which are purified by
chromatography on 60 g of silica gel (0.063-0.2 mm) contained in a
column 2.5 cm in diameter, eluting with a dichloromethane-methanol
mixture (99-1 by volume) and collecting 25 cm.sup.3 fractions.
Fractions 8 to 18 are pooled and concentrated under reduced
pressure (0.27 kPa) at 40.degree. C. 1.35 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-methoxy-
acetoxy-7.beta.-trifluoromethanephonyloxy-9-oxo-11-taxen-13.alpha.-yl
(2R,3S)-3-tert-butoxycarbonylamino-2-(1-ethoxyethoxy)-3-(3-thienyl)propio-
nate are obtained in the form of a white amorphous solid.
[0171]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,13.alpha.-dihydrox-
y-10.beta.-methoxyacetoxy-7.beta.-trifluoromethanesulphonyloxy-9-oxo-11-ta-
xene can be prepared in the following manner:
[0172] To a solution of 10 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-e-
poxy-1,7.beta.,13.alpha.-trihydroxy-10.beta.-methoxyacetoxy-9-oxo-11-taxen-
e in a mixture of 500 cm.sup.3 of dichloromethane and 48 cm.sup.3
anhydrous pyridine, under argon atmosphere, are added dropwise 3.8
cm.sup.3 of trifluoromethanesulphonic anhydride, the temperature
being maintained at 20.degree. C. The reaction mixture is stirred
at the boiling temperature of the solvent for 2 hours. After
cooling to 20.degree. C., 100 cm.sup.3 of water are added. The
aqueous phase is decanted and extracted with 200 cm.sup.3
dichloromethane. The pooled organic phases are washed successively
with 100 cm.sup.3 of water, 100 cm.sup.3 of a saturated aqueous
sodium hydrogen carbonate solution and twice 75 cm.sup.3 of water,
dried over sodium sulphate, filtered and concentrated to dryness
under reduced pressure (2.7 kPa) at 40.degree. C. 11.5 g of a white
amorphous solid are obtained which are purified by chromatography
on 400 g of silica gel (0.063-0.2 mm) contained in a column 4.5 cm
in diameter, eluting with a dichloromethane-methanol mixture (99-1
by volume) and collecting 50 cm.sup.3 fractions. Fractions 15 to 31
are pooled and concentrated under reduced pressure (0.27 kPa) at
40.degree. C. 7.2 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,1-
3.alpha.-dihydroxy-10.beta.-methoxyacetoxy-7.beta.-trifluoromethanesulphon-
yloxy-9-oxo-11-taxene are obtained in the form of a white amorphous
solid.
[0173]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.,13.alpha.--
trihydroxy-10.beta.-methoxyacetoxy-9-oxo-11-taxene can be prepared
in the following manner:
[0174] To a solution of 11 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-e-
poxy-7.beta.-triethylsilyloxy-1,13.alpha.-dihydroxy-10.beta.-methoxyacetox-
y-9-oxo-11-taxene in 500 cm.sup.3 of anhydrous tetrahydrofuran,
under argon atmosphere, are added dropwise 50 cm.sup.3 of hydrogen
fluoride-pyridine, the temperature being maintained at 20.degree.
C. The reaction mixture is stirred at 20.degree. C. for 2 hours,
and supplemented with 10 cm.sup.3 of hydrogen fluoride-pyridine.
The stirring is maintained then for 1 hour at 20.degree. C. A
mixture of 250 cm.sup.3 of water and 250 cm.sup.3 of
dichloromethane is added. The pooled organic phases are washed
successively with twice 75 cm.sup.3 of water, with twice 75
cm.sup.3 of a saturated aqueous sodium hydrogen carbonate solution
and with twice 75 cm.sup.3 of water, dried over sodium sulphate,
filtered and concentrated to dryness under reduced pressure (2.7
kPa) at 40.degree. C. 10 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.-
beta.,13.alpha.-trihydroxy-10.beta.-methoxyacetoxy-9-oxo-11-taxene
are obtained in the form of a white amorphous solid.
[0175]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-7.beta.-triethylsily-
loxy-1,13.alpha.-dihydroxy-10.beta.-methoxyacetoxy-9-oxo-11-taxene
can be prepared according to the international application PCT WO
94/07878 by condensing
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-7.beta.-triethy-
lsilyloxy-1,10.beta.,13.alpha.-trihydroxy-9-oxo-11-taxene with a
methoxyacetyl halogenide.
[0176]
(3R,4S)-1-(tert-butoxycarbonyl)-3-(1-ethoxyethoxy)-4-(3-thienyl)-2--
azetidinone can be prepared in the following manner:
[0177] To a solution of 10 g of
(3R,4S)-3-(1-ethoxyethoxy)-4-(3-thienyl)-2- -azetidinone in 400
cm.sup.3 of dichloromethane, under argon atmosphere, are added 12
cm.sup.3 of triethylamine and 0.1 g of 4-dimethylaminopyridine, and
then, dropwise at 0.degree. C., a solution of 13.5 g of
di-tert-butyl dicarbonate in 100 cm.sup.3 of dichloromethane. The
reaction mixture is warmed at 20.degree. C. and maintained at
20.degree. C. for 24 hours, and then 100 cm.sup.3 of water are
added. The aqueous phase is decanted and extracted with 100
cm.sup.3 of dichloromethane. The pooled organic phases are washed
twice with 50 cm.sup.3 of water, dried over sodium sulphate,
filtered and concentrated to dryness under reduced pressure (2.7
kPa) at 40.degree. C. 15 g of a white amorphous solid are obtained
which are purified by chromatography on 240 g of silica gel
(0.063-0.2 mm) contained in a column 4.5 cm in diameter, eluting
with a dichloromethane-methanol mixture (99-1 by volume) and
collecting 50 cm.sup.3 fractions. Fractions 7 to 18 are pooled and
concentrated under reduced pressure (0.27 kPa) at 40.degree. C. 12
g of
(3R,4S)-1-(tert-butoxycarbonyl)-3-(1-ethoxyethoxy)-4-(3-thieny-
l)-2-azetidinone are obtained in the form of a white amorphous
solid.
[0178] (3R,4S)-3-(1-ethoxyethoxy)-4-(3-thienyl)-2-azetidinone can
be prepared in the following manner:
[0179] To a solution of 10 g of
(3R,4S)-3-hydroxy-4-(3-thienyl)-2-azetidin- one in 200 cm.sup.3
tetrahydrofuran, under an argon atmosphere, are added 0.3 g of
pyridinium toluene-4-sulphonate, then, dropwise, at 20.degree. C.,
28.2 cm.sup.3 of ethyl vinyl ether. The reaction mixture is stirred
and heated at 60.degree. C. for 2 hours and concentrated to dryness
under reduced pressure (2.7 kPa) at 40.degree. C. 500 cm.sup.3 of
ethyl acetate are added and the mixture is washed with 5 times 75
cm.sup.3 of water, dried over sodium sulphate, filtered and
concentrated to dryness under reduced pressure (2.7 kPa) at
40.degree. C. 14.5 g of a brown oil are obtained which are purified
by chromatography on 240 g of silica gel (0.063-0.2 mm) contained
in a column 4.5 cm in diameter, eluting with a
dichloromethane-methanol mixture (99.5-0.5 by volume) and
collecting 50 cm.sup.3 fractions. Fractions 13 to 21 are pooled and
concentrated under reduced pressure (0.27 kPa) at 40.degree. C.
10.2 g of (3R,4S)-3-(1-ethoxyethoxy)-4-(3-thienyl)-2-azetidinone
are obtained in the form of pale yellow crystals melting at
60.degree. C.
[0180] (3R,4S)-3-hydroxy-4-(3-thienyl)-2-azetidinone can be
prepared according to the method described in international
application PCT WO 94/24103.
EXAMPLE 7
[0181] A solution of 470 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-ep-
oxy-1-hydroxy-10.beta.-methoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-n-
or-11-taxen 13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methox-
yphenyl)-4-phenyl-5-oxazolidinecarboxylate in 4.8 cm3 of a 0.1N
solution of HCl in ethanol is stirred at 5.degree. C. under an
argon atmosphere for 17 hours. The reaction mixture is then diluted
with a mixture of 5 cm.sup.3 of dichloromethane, 5 cm.sup.3 of a
saturated aqueous sodium hydrogen carbonate solution and 2.5
cm.sup.3 of water. The aqueous phase is extracted with 5 cm3 of
dichloromethane. The pooled organic phases are washed with 5
cm.sup.3 of water, dried over magnesium sulphate, filtered and
concentrated to dryness under reduced pressure. 380 mg of a yellow
foam are obtained which are chromatographed at atmospheric pressure
on 15 g silica gel (0.063-0.2 mm) contained in a column 1.7 cm in
diameter, eluting with a dichloromethane-methanol mixture (98-2 by
volume). 300 mg of deprotected product are obtained which are
purified by chromatography on silica gel plates (10 plates,
20.times.20 cm, thickness=0.5 mm), eluting with a
dichloromethane-methanol mixture (95-5 by volume). 142 mg of pure
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-
-methoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.--
yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate
are obtained in the form of a white foam whose characteristics are
the following:
[0182] specific rotation: [.alpha.].sup.20.sub.D=-35.8 (c=0.25,
methanol)
[0183] proton NMR spectrum (400 MHz, CDCl.sub.3, .delta. in ppm,
coupling constants J in Hz):
[0184] 1.27 (s, 3H: CH.sub.3); 1.28 (s, 3H: CH.sub.3); 1.30 (s, 9H:
C(CH.sub.3).sub.3); 1.40 (m, 1H: H 7); 1.69 and 2.25 (2m, 1H each:
CH.sub.219); 1.86 (s, 1H: OH); 1.87 (s, 3H: CH.sub.3); 2.13 and
2.48 (respectively: broad d and dt, J=16, J=16 and 4.5, 1H each:
CH.sub.2 6); 2.23 and 2.39 (2m, 1H each: CH.sub.2 14); 2.40 (s, 3H:
COCH.sub.3); 3.27 (m, 1H: OH 2'); 3.53 (s, 3H: OCH.sub.3); 4.03 and
4.32 (2 d, J=9, 1H each: CH.sub.2 20); 4.10 (d,J=7, 1H: H 3); 4.22
(AB limit, J=16, OCOCH.sub.2); 4.62 (m, 1H: H 2'); 4.74 (d,J=4.5,
1H: H 5); 5.29 (m, 1H: H 3'); 5.35 (d,J=10, 1H: CONH); 5.67 (d,J=7,
1H: H 2); 6.28 (broad t,J=9, 1H: H 13); 6.42 (s, 1H: H 10); 7.30 to
7.45 (m, 5H: H 3'-phenyl); 7.51 (t,J=7.5, 2H:
OCOC.sub.6H.sub.5-meta); 7.61 (t, J=7.5, 2H:
OCOC.sub.6H.sub.5H-para); 8.15 (t,J=7.5, 2H: OCOC.sub.6H.sub.5
H-ortho).
[0185]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-m-
ethoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxaz-
olidinecarboxylate can be prepared in the following manner:
[0186] To a solution of 1.1 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20--
epoxy-1-hydroxy-10.beta.-methoxyacetoxy-7.beta.-trifluoromethanesulphonylo-
xy-9-oxo-11-taxen-13.alpha.-yl
(2R,4S,SR)-3-tert-butoxycarbonylamino-2-(4--
methoxyphenyl)-4-phenyl-5-oxazolidinecarboxylate in a mixture of 11
cm.sup.3 of anhydrous acetonitrile and 1.5 cm.sup.3 of anhydrous
tetrahydrofuran, maintained under an argon atmosphere, are added
0.2 g of powdered 4 .ANG. molecular sieve and 0.88 g of sodium
chloride. The reaction mixture is stirred for a few minutes at a
temperature close to 20.degree. C., then heated at the boiling
temperature of the solvent for 2 hours. After cooling at a
temperature close to 20.degree. C., the reaction mixture is
filtered and concentrated to dryness under reduced pressure. 1.5 g
of a yellow oil are obtained which are purified by chromatography
at atmospheric pressure on 50 g of silica gel (0.063-0.2 mm)
contained in a column 3 cm in diameter, eluting with a
dichloromethane-methanol mixture (9-1 by volume). 480 mg of pure
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-methoxy-
acetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxaz-
olidinecarboxylate is obtained in the form of an ivory foam.
[0187]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-m-
ethoxyacetoxy-7.beta.-trifluoromethanesulphonyloxy-9-oxo-11-taxen-13.alpha-
.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5--
oxazolidinecarboxylate can be prepared in the following manner:
[0188] To a solution of 1.0 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20--
epoxy-1,13.alpha.-dihydroxy-10.beta.-methoxyacetoxy-7.beta.-trifluorometha-
nesulphonyloxy-9-oxo-11-taxene and 0.94 g of
(2R,4S,5R)-3-tert-butoxycarbo-
nylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxazolidinecarboxylic acid
in 10 cm.sup.3 of anhydrous toluene are added at a temperature
close to 20.degree. C., under an argon atmosphere, 0.3 g of
powdered 4 .ANG. molecular sieve, 0.63 g of
1,3-dicyclohexylcarbodiimide and 0.15 g of 4-dimethymaminopyridine.
The reaction mixture is stirred at a temperature close to
20.degree. C. under an argon atmosphere for 30 minutes, then
filtered and concentrated to dryness under reduced pressure. 2.1 g
of a yellow foam are obtained which are purified by chromatography
at atmospheric pressure on 60 g of silica gel (0.063-0.2 mm)
contained in a column 2.5 cm in diameter, eluting with a
cyclohexane-ethyl acetate mixture (1-1 by volume). 1.17 g of pure
4-acetoxy-2.alpha.-benzoyloxy-5.b-
eta.,20-epoxy-1-hydroxy-10.beta.-methoxyacetoxy-7.beta.-trifluoromethanesu-
lphonyloxy-9-oxo-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylami- no-2-(methoxy-4
phenyl)-4-phenyl-5-oxazolidinecarboxylate are obtained in the form
of a light yellow foam.
EXAMPLE 8
[0189] 180 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy--
10.beta.-butoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.-
alpha.-yl (2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxy
phenyl)-4-phenyl-5-oxazolidinecarboxylate are dissolved in 3.5
cm.sup.3 of 0.1N HCl in ethanol. The solution is stirred for 2
hours at a temperature close to 20.degree. C. Then is added a
mixture of 80 cm.sup.3 of dichloromethane and of 10 cm.sup.3 of a
saturated aqueous solution of sodium hydrogen carbonate. After
decantation, the aqueous phase is extracted with 10 cm.sup.3 of
dichloromethane. The organic phases are pooled and washed with 3
times 10 cm.sup.3 of distilled water, dried over magnesium
sulphate, filtered and concentrated to dryness under reduced
pressure (2.7 kPa) at 40.degree. C. 155 mg of a white foam are
obtained which are purified by chromatography on 7.5 g of silica
gel (0.063-0.2 mm) contained in a column 1 cm in diameter, eluting
with a dichloromethane-methanol mixture (99-1 by volume) and
collecting 5 cm.sup.3 fractions. The fractions containing only the
desired product are pooled and concentrated under reduced pressure
(0.27 kPa) at 20.degree. C. for 16 hours. 98 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy--
1-hydroxy-10.beta.-butoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-
-taxen-13.alpha.-yl
(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylp- ropionate
are obtained in the form of a white foam whose characteristics are
the following:
[0190] specific rotation: [.alpha.].sub.D.sup.20=-32 (c=0.5,
methanol)
[0191] proton NMR spectrum (300 MHz, CDCl.sub.3, .delta. in ppm,
coupling constants J in Hz): 0.97 (s,3H:--OC.sub.4H.sub.9
(--CH.sub.3); 1.28 (s,3H:--CH.sub.3 16 or 17); 1.31 (s, 12H:
C(CH.sub.3).sub.3 and CH.sub.3 16 or 17); 1.38 (mt, 1H: H 7); 1.43
and 1.65 (2 mt, 2H each:
OC.sub.4H.sub.9(OCH.sub.2CH.sub.2CH.sub.2CH.sub.3); 1.72 and 2.26
(2 mt, 1H each: CH.sub.2 19); 1.87 (s, 1H: OH); 1.89 (s, 3H:
--CH.sub.3); 2.15 and 2.50 (respectfully broad d and dt, J=16 and
J=16 and 4.5, 1H each: CH.sub.26); 2.25 and 2.41 (respectively dd
and mt, J=16 and 9, 1H each: CH.sub.2 14); 2.42 (s,3H: COCH.sub.3);
3.28 (mt, 1H: OH 2'); 3.65 (t,J=7.5, 2H: OC.sub.4H.sub.9); 4.07 and
4.35 (2 d,J=9, 1H each: CH.sub.220); 4.12 (d,J=7.5, 1H: H 3); 4.28
(AB limit, J=17, 2H: OCOCH.sub.2O); 4.65 (mt, 1H: H 2'); 4.76
(d,J=4.5, 1H: H 5); 5.31 (broad d,J=10, 1H: H 3'); 5.38 (d,J=10,
1H: CONH); 5.70 (d,J=7.5, 1H: H 2); 6.29 (broad t,J=9, 1H: H 13);
6.43 (s, 1H: H 10); from 7.25 to 7.45 (mt, 5H: C.sub.6H.sub.53');
7.52 [(t,J=7.5, 2H: OCOC.sub.6H.sub.5(H 3 and H 5)]; 7.63
[(t,J=7.5, 1H: OCOC.sub.6H.sub.5(H 4)]; 8.18 [(d,J=7.5, 2H:
OCOC.sub.6H.sub.5(H 2 and H 6)].
[0192]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-b-
utoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,4S,SR)-3-tert-butoxycarbonylamino-2-(methoxy-4phenyl)-4-phenyl-5-oxaz-
olidinecarboxylate can be prepared in the following manner:
[0193] To a solution of 0.015 cm.sup.3 of butoxyacetic acid in 5
cm.sup.3 of anhydrous toluene, maintained under an argon atmosphere
and stirred, are added 100 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,10.b-
eta.-dihydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-y-
l
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxa-
zolidinecarboxylate, 7 mg of 4-dimethylaminopyridine and 40 mg of
1,3-dicyclohexylcarbodiimide. The reaction mixture is stirred for 2
hours at a temperature close to 20.degree. C. then filtered on
sintered glass filter provided with celite. The filter is rinsed
with 100 cm.sup.3 of ethyl acetate. The filtrates are pooled,
washed with 4 times 8 cm.sup.3 of distilled water, dried over
magnesium sulphate, filtered and concentrated under reduced
pressure (2.7 kPa) at 40.degree. C. 128 mg of a white foam are
obtained which are purified by chromatography on 7.5 g of silica
gel (0.063-0.2 mm) contained in a column 1 cm in diameter, eluting
with a dichloromethane-methanol mixture (99-1 by volume) and
collecting 10 cm.sup.3 fractions. The fractions containing only the
desired product are pooled and concentrated under reduced pressure
(2.7 kPa) at 40.degree. C. 94 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-e-
poxy-1-hydroxy-10.beta.-butoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-n-
or-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methox-
yphenyl)-4-phenyl-5-oxazolidinecarboxylate are obtained in the form
of a white foam.
[0194]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,10.beta.-dihydroxy-
-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxaz-
olidinecarboxylate can be prepared in the following manner:
[0195] To a solution of 12.5 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-
-epoxy-1-hydroxy-10.beta.-methoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-1-
9-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-met-
hoxyphenyl)-4-phenyl-5-oxazolidinecarboxylate in 850 cm.sup.3 of
anhydrous methanol, maintained under an argon atmosphere, are added
at a temperature close to 20.degree. C., 37.5 g of powdered 4 .ANG.
molecular sieve and 6.52 g of zinc iodide. The reaction mixture is
stirred for 5 hours at a temperature close to 20.degree. C. and
then concentrated to dryness under reduced pressure (2.7 kPa) at
40.degree. C. The solid obtained is dissolved in 850 cm.sup.3 of
ethyl acetate and 150 cm.sup.3 of distilled water are added. The
reaction mixture is stirred for 10 minutes and the insoluble
material is filtered on sintered glass filter. The sintered glass
filter is rinsed with 100 cm.sup.3 of ethyl acetate. The filtrates
are pooled and the aqueous phase is separated by decantation and
extracted with 100 cm.sup.3 of ethyl acetate. The organic phases
are pooled, washed with 3 times of distilled water, dried over
magnesium sulphate, filtered and concentrated under reduced
pressure (2.7 kPa) at 40.degree. C. 12.2 g of a yellow foam are
obtained which are purified by chromatography on 425 g of silica
gel (0.063-0.2 mm) contained in a column 6 cm in diameter, eluting
with a dichloromethane-methanol mixture (99-1 by volume) and
collecting 100 cm.sup.3 fractions. The fractions containing only
the desired product are pooled and concentrated under reduced
pressure (0.27 kPa) at 20.degree. C. for 16 hours. 8.62 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-
-1,10.beta.-dihydroxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.a-
lpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-pheny-
l-5-oxazolidinecarboxylate are obtained in the form of a white
foam.
[0196]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-m-
ethoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxaz-
olidinecarboxylate can be prepared in the following manner:
[0197] To a solution of 8.24 g of (2R,4S,5R)-3-tert
butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxazolidinecarboxylic
acid in 470 cm.sup.3 of ethyl acetate, maintained under an argon
atmosphere and stirred, are added, at a temperature close to
20.degree. C., 10.33 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,13.alpha.-
-dihydroxy-10.beta.-methoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor--
11-taxene, 1.1 g of 4-dimethylaminopyridine and 6.23 g of
1,3-dicyclohexylcarbodiimide. The reaction mixture is stirred for 2
hours at a temperature close to 20.degree. C., then filtered on
sintered filter glass provided with celite. The sintered glass
filter is washed with 3 times 100 cm.sup.3 of ethyl acetate. The
filtrates are pooled, washed successively with 3 times 150 cm.sup.3
of distilled water, 100 cm.sup.3 of a saturated solution of sodium
hydrogen carbonate and with twice 150 cm.sup.3 of distilled water,
dried over magnesium sulphate, filtered and concentrated to dryness
under reduced pressure (2.7 kPa) at 40.degree. C. 21.2 g of a
yellow foam are obtained which are purified by chromatography on
900 g of silica gel (0.063-0.2 mm) contained in a column 7 cm in
diameter, eluting with a dichloromethane-methanol mixture (99-1 by
volume) and collecting 100 cm.sup.3 fractions. The fractions
containing only the desired product are pooled and concentrated
under reduced pressure (0.27 kPa) at 40.degree. C. 15.47 g of
4-acetoxy-2.alpha.-benzoy-
loxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-methoxyacetoxy-7.beta.,8.beta.-me-
thylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbony-
lamino-2-(4-methoxyphenyl)-4-phenyl-5-oxazolidinecarboxylate are
obtained in the form of a white foam.
[0198]
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl--
5-oxazolidine-carboxylic acid can be prepared in the following
manner:
[0199] A solution of 10.0 g of methyl
(2R,3S)-3-tert-butoxycarbonylamino-2- -hydroxy-3-phenylpropionate
and of 0.25 g of pyridinium 4-toluenesulphonate in 200 cm.sup.3 of
toluene is dehydrated by distillation of 20 cm.sup.3 of solvent.
6.34 cm.sup.3 of 4-methoxybenzaldehyde dimethylacetate is added in
the course of 5 minutes and the reaction mixture heated at the
boiling temperature. During the addition, 50 cm.sup.3 of solvent
are distilled and then 100 cm.sup.3 of solvent are still distilled.
After cooling at a temperature close to 20.degree. C., 80 cm.sup.3
of cyclohexane are added in the course of 10 minutes. The reaction
mixture is cooled to 0-5.degree. C. and filtered on sintered glass
filter. The precipitate is washed with 40 cm.sup.3 of cyclohexane
and dried under reduced pressure at a temperature close to
20.degree. C. 10.9 g of
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methox-
yphenyl)-4-phenyl-5-oxazolidine-carboxylic acid are obtained in 74%
yield.
[0200]
4-Acetoxy-2.alpha.-benzoyloxy-5.alpha.,20-epoxy-1,13.alpha.-dihydro-
xy-10.beta.-methoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-
e can be prepared in the following manner:
[0201] To a solution of 15.37 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,2-
0-epoxy-1,13.alpha.-dihydroxy-10.beta.-methoxyacetoxy-7.beta.-trifluoromet-
hanesulphonyloxy-9-oxo-11-taxene in a mixture of 310 cm.sup.3 of
acetonitrile and of 31 cm.sup.3 of anhydrous tetrahydrofuran,
maintained under an argon atmosphere and stirred, are added 9 g of
powdered 4 .ANG. molecular sieve and 24 g of sodium chloride. The
reaction mixture is stirred for 30 minutes at a temperature close
to 20.degree. C. and then at the boiling point (75.degree. C.) for
2.5 hours. After cooling at a temperature close to 20.degree. C.,
the reaction mixture is filtered on sintered glass filter. The
sintered glass filter is washed with 4 times 400 cm.sup.3 and the
pooled filtrates are washed successively with 4 times 300 cm.sup.3
of distilled water, 250 cm.sup.3 of a saturated solution of sodium
hydrogen carbonate and with 250 cm.sup.3 of distilled water, dried
over magnesium sulphate, filtered and concentrated to dryness under
reduced pressure (2.7 kPa) at 40.degree. C. 2.12 g of a white foam
are obtained which are purified by chromatography on 750 g of
silica gel (0.063-0.2 mm) contained in a column 6 cm in diameter,
eluting with a dichloromethane-methanol mixture (99-1 by volume)
and collecting 100 cm.sup.3 fractions. The fractions containing
only the desired product are pooled and concentrated under reduced
pressure (0.27 kPa) at 40.degree. C. 10.35 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-
,13.alpha.-dihydroxy-10.beta.-methoxyacetoxy-7.beta.,8.beta.-methylene-9-o-
xo-19-nor-11-taxene are obtained in the form of a white foam.
[0202]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,13.alpha.-dihydrox-
y-10.beta.-methoxyacetoxy-7.beta.-trifluoromethanesulphonyloxy-9-oxo-11-ta-
xene can be prepared in the following manner:
[0203] To a solution of 19.1 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-
-epoxy-1,7.beta.,13.alpha.-trihydroxy-10.beta.-methoxyacetoxy-9-oxo-11-tax-
ene in 900 cm.sup.3 of dichloromethane, maintained under an argon
atmosphere and stirred, are added, at a temperature close to
20.degree. C., 9.9 cm.sup.3 of anhydrous pyridine and then, slowly,
6.3 cm.sup.3 of trifluoromethanesulphonic anhydride. The reaction
mixture is stirred for 15 minutes at a temperature close to
20.degree. C. and then heated to 40.degree. C. for 2 hours. After
cooling at a temperature close to 20.degree. C., the reaction
mixture is poured in 250 cm.sup.3 of distilled water. The aqueous
phase is separated by decantation and extracted with twice 30
cm.sup.3 of dichloromethane. The organic phases are pooled, dried
over magnesium sulphate, filtered and concentrated under reduced
pressure (2.7 kPa) at 40.degree. C. 25.12 g of an orange foam are
obtained which are purified by chromatography on 900 g of silica
gel (0.063-0.2 mm) contained in a column 6.5 cm in diameter,
eluting with a dichloromethane-methanol mixture (99-1 by volume)
and collecting 100 cm.sup.3 fractions. The fractions containing
only the desired product are pooled and concentrated under reduced
pressure (2.7 kPa) at 40.degree. C. 15.37 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,13.alpha.-dih-
ydroxy-10.beta.-methoxyacetoxy-7.beta.-trifluoromethanesulphonyloxy-9-oxo--
11-taxene are obtained.
[0204]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.,13.alpha.--
trihydroxy-10.beta.-methoxyacetoxy-9-oxo-11-taxene can be prepared
in the following manner:
[0205] To a solution of 22.4 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.-20-
-epoxy-1,13.alpha.-dihydroxy-7.beta.-triethylsilyloxy-10.beta.-methoxyacet-
oxy-9-oxo-11-taxene in 225 cm3 of dichloromethane, maintained under
an argon atmosphere and stirred, are added dropwise at a
temperature close to 0.degree. C., 374 cm3 of a complex of
fluorhydric acid and triethylamine (3-1 by mole). The reaction
mixture is heated to a temperature close to 20.degree. C. and
maintained at this temperature for 2.5 hours and then, maintaining
the temperature close to 20.degree. C., poured in 1800 cm.sup.3 of
a saturated solution of sodium hydrogen carbonate. The pH of the
aqueous phase is adjusted to 7-8 by addition, very slowly and under
vigorous stirring, of 200 g of sodium hydrogen carbonate. The 350
cm.sup.3 of dichloromethane are added and the insoluble material is
separated by filtration on a sintered glass filter. The sintered
glass filter is washed twice with 100 cm.sup.3 of dichloromethane.
The aqueous phase is separated by decantation and extracted with
twice 200 cm.sup.3 of dichloromethane. The organic phases are
pooled and washed with 3 times 150 cm.sup.3 of distilled water,
dried over magnesium sulphate, filtered and concentrated under
reduced pressure (2.7 kPa) at 40.degree. C. 19.1 g of
4-acetoxy-2.alpha.-benzoyoloxy-5.bet-
a.,20-epoxy-1,7.beta.,13.alpha.-trihydroxy-10.beta.-methoxyacetoxy-9-oxo-1-
1-taxene are obtained in the form of a beige foam.
[0206]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,13.alpha.-dihydrox-
y-7.beta.-triethylsilyloxy-10.beta.-methoxyacetoxy-9-oxo-11-taxene
can be prepared in the following manner:
[0207] To a solution of 43.5 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-
-epoxy-1,10.beta.,13.alpha.-trihydroxy-7.beta.-triethylsilyloxy-9-oxo-11-t-
axene in 500 cm.sup.3 of anhydrous pyridine, maintained under under
an argon atmosphere and stirred, are added dropwise, in the course
of 75 minutes and at a temperature close to 5.degree. C., 430 g of
methoxyacetic chloride. The reaction mixture is heated at
20.degree. C., stirred for 24 hours and then poured in 8000
cm.sup.3 of water at a temperature close to 5.degree. C. After 15
minutes the reaction mixture is filtered on sintered glass filter.
The sintered glass filter is washed with 3 times 250 cm.sup.3 of
ethyl acetate. The decanted organic phase is washed with 4 times
500 cm.sup.3 of distilled water, dried over magnesium sulphate and
concentrated to dryness under reduced pressure (2.7 kPa) at
40.degree. C. 92 g of a brown foam is obtained which is taken in
250 cm.sup.3 of diisopropyl ether. The suspension is stirred for 1
hour at a temperature close to 20.degree. C., filtered on a
sintered glass filter, washed with twice 100 cm.sup.3 of
diisopropyl ether and dried under reduced pressure (2.7 kPa) at
20.degree. C. for 16 hours. 69 g of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,13.alpha.-dihydroxy-7.be-
ta.-triethylsilyloxy-10.beta.-methoxyacetoxy-9-oxo-11-taxene are
obtained in the form of a beige foam.
[0208]
4-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-10.beta.,13.alpha.-
-trihydroxy-7.beta.-triethylsilyloxy-9-oxo-11-taxene can be
prepared according to the method described by J-N. Denis et al., J.
Amer. Chem. Soc., 110 5917-5919 (1988).
EXAMPLE 9
[0209] Using the procedure described in Example 8 but starting with
168 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-etho-
xyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxaz-
olidinecarboxylate, 97 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epox-
y-1-hydroxy-10.beta.-ethoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor--
11-taxen-13.alpha.-yl
(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-pheny- lpropionate
are obtained in the form of a white foam whose characteristics are
the following:
[0210] specific rotation: [.alpha.].sub.D.sup.20=-34 (c=0.5,
methanol)
[0211] proton NMR spectrum (300 MHz, CDCl.sub.3, .delta. in ppm,
coupling (constants J in Hz) 1.28 (s, 3H: CH.sub.3 16 or 17); 1.31
(s, 15H: C(CH.sub.3).sub.3, OCH.sub.2CH.sub.3 and CH.sub.3 16 or
17); 1.42 (mt, 1H: H 7); 1.72 and 2.26 (respectively dd and mt, J=7
and 5, 1H each: CH.sub.2 19); 1.87 (s, 1H: OH 1); 1.89 (s, 3H:
CH.sub.3); 2.15 and 2.50 (respectively: broad d and dt, J=16 and
J=16 and 4.5, 1H each: CH.sub.2-6); 2.26 and 2.41 (respectively dd
and mt, J=16 and 9, 1H each: CH.sub.2 14); 2.41 (s, 3H:
COCH.sub.3); 3.28 (mt, 1H: OH 2'); 3.71 (q,J=7.5, 2H:
OCH.sub.2CH.sub.3); 4.05 and 4.35 (2 d,J=9, 1H each: CH.sub.2 20);
4.14 (d,J=7.5, 1H: H3); 4.30 (AB limit, J=17, 2H: OCOCH.sub.2O);
4.63 (mt, 1H: H 2'); 4.76 (d,J=4.5 Hz, 1H: H 5); 5.29 (broad
d,J=10, 1H: H 3'); 5.38 (d,J=10, 1H: CONH); 5.70 (d,J=7.5, 1H: H
2); 6.30 (broad t; J=9, 1H: H 13); 6.45 (s, 1H: H 10); from 7.30 to
7.50 (mt, 5H: C.sub.6H.sub.53'); 7.54 [(t,J=7.5, 2H:
OCOC.sub.6H.sub.5 (H3 and H5)]; 7.62 [t,J=7.5, 1H:
OCOC.sub.6H.sub.5(H4)]; 8.18 [(d,J=7.5 2H: OCOC.sub.6H.sub.5(H 2
and H 6)].
[0212] Using the procedure described in Example C but starting with
200 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,10.beta.-dihydroxy-7.-
beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl(2R,4S,5R)-3-ter-
t-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxazolidinecarboxylat-
e, 168 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.b-
eta.-ethoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alph-
a.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-
-oxazolidinecarboxylate in the form of a white foam.
EXAMPLE 10
[0213] Using the procedure described in Example 8 but starting with
253 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-10.beta.-isop-
ropoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxaz-
olidinecarboxylate, 156 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epo-
xy-1-hydroxy-10.beta.-isopropoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-
-nor-11-taxen-13.alpha.-yl
(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-- phenylpropionate
are obtained in the form of a white foam whose characteristics are
the following:
[0214] specific rotation: [a].sub.D.sup.20=-39 (c=0.5,
methanol)
[0215] proton NMR spectrum (300 MHz, CDCl.sub.3, .delta. in ppm,
coupling constants J in Hz) From 1.20 to 1.45 (mt, 21H: CH.sub.3 16
or 17, CH.sub.3 16 or 17, --C(CH.sub.3).sub.3 and
--OCH(CH.sub.3).sub.2); 1.38 (mt, 1H: H 7); 1.68 and 2.26
(respectively dd and mt, J=6.5 and 5.5, 1H each: CH.sub.2 19); 1.84
(s, 1H: OH 1); 1.87 (s, 3H: CH.sub.3); 2.10 and 2.47 (respectively
broad d and dt, J=16 and J=16 and 4.5, 1H each: CH.sub.2 6); 2.24
and 2.39 (respectively dd and mt, J=16 and 9, 1H each: CH.sub.2
14); 2.40 (s, 3H: COCH.sub.3); 3.25 (mt, 1H: OH 2'); 3.78 [(mt, 1H
OCH(CH.sub.3).sub.3]; 4.03 and 4.32 (2 d,J=9, 1H each: CH.sub.2
20); 4.10 (d,J=7.5, 1H: H 3); 4.26 (AB limit, J=16, 2H:
OCOCH.sub.2O); 4.62 (mt, 1H: H 2'); 4.73 (d,J=4.5, 1H: H 5); 5.29
(broad d,J=10, 1H: H 3'); 5.35 (d,J=10, 1H: CONH); 5.67 (d, J=7.5,
1H: H 2); 6.27 (broad t,J=9, 1H H 13); 6.41 (s, 1H: H 10); from
7.25 to 7.50 (mt, 5H: C.sub.6H.sub.5 3'); 7.51 [(t,J=7.5, 2H:
OCOC.sub.6H.sub.5(H3 and H 5)]; 7.61 [t,J=7.5, 1H:
OCOC.sub.6H.sub.5(H 4)]; 8.16 [(d,J=7.5, 2H: OCOC.sub.6H.sub.5(H 2
and H 6)].
[0216] Using the procedure described in Example C but starting with
300 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,10.beta.-dihydroxy-7.-
beta.,8.beta.-methylene-9-oxo-19-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-methoxyphenyl)-4-phenyl-5-oxaz-
olidinecarboxylate, 253 mg of
4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epo-
xy-1-hydroxy-10.beta.-isopropoxyacetoxy-7.beta.,8.beta.-methylene-9-oxo-19-
-nor-11-taxen-13.alpha.-yl
(2R,4S,5R)-3-tert-butoxycarbonylamino-2-(4-meth-
oxyphenyl)-4-phenyl-5-oxazolidinecarboxylate in the form of a white
foam.
[0217] Although the invention has been described in conjunction
with specific embodiments, it is evident that many alternatives and
variations will be apparent to those skilled in the art in light of
the foregoing description. Accordingly, the invention is intended
to embrace all of the alternatives and variations that fall within
the spirit and scope of the appended claims. The above references
are hereby incorporated by reference.
* * * * *